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Part I 
Introduction and scope 

1 
Introduction to drug safety 

introductioll to drug safety 
They who make it their profession to sell or prescribe drugs can)' a shared 
responsibility for the mOllitoring of drug safety (Yearly report, Netherlallds 
Centre for MOllitorillg of Adverse Reactiolls to Drugs, i993). 
1.1 What is drug safety? 
Drug safety is an important palt of postmarketing surveillance. In ancient 
times, people were already aware of the fact that drugs could have side effects. 
The oldest drugs were mainly of plant and animal origin, but also mercury, 
arsenic and antimony were used, the toxic effects of which were well known. 
In 1224 Frederick II, Emperor of Hohenstaufen ordered inspection of drugs 
and mixtures prepared by apothecaries and in 1518 the Royal college of 
Physicians was founded, whose Fellows were also concemed with quality 
control of drugs. The first drug to be banned because of its toxicity was 
antimony in the 17th century. It was used again, however, after it cured Louis 
XIV from typhoid fever. 
One of the first descriptions of an intoxication to a drug which is still in use 
today, was made by William Withering in 1785. He described digitalis 
intoxication as follows: "The Foxglove, when given in very large and quickly 
repeated doses, occasions sickness, vomiting, purging, giddiness, confused 
vision, objects appearing green or yellow, increased secretion of urine with 
frequent motions to patt with it, and sometimes inability to retain it; slow 
pulse, even as low as 35 in a minute, cold sweats, convulsions, syncope and 
death" [1). 
In the same era, calomel (mercurous chloride), often mixed with other 
purgatives, was used to treat yellow fever. Many patients survived this 
treatment, perhaps aided by the vomiting they already did. Others developed 
mercurialism with intense salivation, loosening of the teeth, ulceration 
(sometimes even gangrene) of mouth and cheeks, and osteomyelitis of the 
mandible. In the 19th century, however, calomel was used as a treatment for 
all febrile diseases. Some laymen understood the danger of calomel, and after a 
while physicians started to add to their protests. Holmes wrote in 1861: "if the 
whole materia medica, as it is now used, could be sunk to the bottom of the 
sea, it would be all the better for mankind - and all the worse for the fishes". 
In the 19th century, the first pharmacopoeias were made, and at the end of 
this century and the beginning of the 20th the first formal enquiries into 
suspected adverse reactions to drugs were made: sudden death during 
chloroform anaesthesia, and jaundice after arsenical treatment of syphilis. Not 
until the end of the 1930's, a Federal Act was introduced in the U.S.A. which 
forbade the marketing of new drugs until they had been cleared for safety by 
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the Food and Dmg Administration. In The Netherlands, however, such 
legislation was implemented as late as the early fifties. 
In 1961, it was discovered that the popular hypnotic thalidomide was an 
important teratogenic agent. This led to the institution of the Netherlands 
Centre for Monitoring of Adverse Reactions to Dmgs in 1963, as well as to 
the establishment of other dmg safety offices worldwide. Later, the World 
Health Organization (WHO) set up an international bureau to collect data on 
adverse reactions to dmgs from all over the world. Today, this system is still 
in use: a computer link to Sweden (Uppsala) connects all dmg safety offices in 
Europe and gives them access to a large databank. All countries linked to the 
system also have to feed the databank with their data on adverse reactions to 
dmgs. Every year, a meeting is organized by the WHO in order to discuss dmg 
safety items that have come up during the past year. CUlTently, the European 
Community plans to implement a similar network. 
Aided by the number of law suits to pharmaceutical companies and the often 
exaggerated presentation by the media, dmg safety has received much attention 
during the past 30 years. PhalTllacentical filTlls take great care in order to 
ensure that all possible adverse reactions will be mentioned in their product 
information sheets, in order to prevent law suits obliging the payment of large 
sums of money to the victims of suspected adverse reactions to their dmg. 
However, the field of dmg safety has mainly focused on voluntary reporting in 
the past decades, and systems and methods for postmarketing surveillance have 
not been fully developed yet. There are some special problems involved when 
studying adverse reactions to dmgs. 
As mentioned, dmg safety is an important part of postrnarketing 
surveillance. Postrnarketing surveillance, however, encompasses more than dmg 
safety. According to the Dutch Health Council, postmarketing surveillance is 
systematic surveillance of and scientific research into all desired and undesired 
(side) effects of dmgs on health, as soon as these dmgs are marketed. 
Therefore, postmarketing surveillance should yield data needed for rational and 
safe use of dmgs, but, strictly speaking, also of medical devices. It not only 
encompasses the area of research into side effects of dmgs, but also the 
research of efficacy and effectiveness of dmgs [2]. Although the definition 
formally pertains to dmgs used by humans, also veterinary dmgs are subject to 
postrnarketing surveillance. 
The safety and efficacy of a dmg are investigated in depth during the 
premarketing phase. After production and selection of a chemical entity with 
therapeutic potential, the phalTllacological and toxicological effects of new 
dmgs are first studied in animals. The LD 50 for several animal species are 
assessed (Le. the dose at which 50 % of animals die due to the toxic effect of 
the dmg), and the effect of the dmg on animals is investigated. Then, Phase I 
to III studies are perfOimed, in which dmgs are first tested on healthy 
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volunteers and later on patients with the disease against which the drug is 
supposed to be effective. However, by the time a drug is marketed, clinical 
experience is still limited. 
This thesis will discuss the pharmacoepidemiologic approach to drug safety 
in the postmarketing phase. Pharmacoepidemiology studies the frequency, 
distribution and determinants of diseases in populations, with the drug as one 
of the determinants. Safety is often described in tenns of adverse effects or 
adverse reactions, side effects or adverse events. Often, the meaning of these 
terms is misunderstood. Hence, the definitions of these terms are given below: 
- An "adverse effect" or "adverse drug reaction" is defined by the World 
Health Organization as "one which is noxious and unintended, and which 
occurs at doses used in man for prophylaxis, diagnosis or therapy". The 
important part missing from this definition, however, is the causal relationship. 
A drug should of course have been used within a proper time window before 
the event (challenge), a reversible event should subside after discontinuation 
(dechallenge), and if the drug is readministered, a similar reaction would be 
expected (rechallenge). 
- A "side effect" is every unintended effect caused by a drug used in 
therapeutic doses. This effect can be wanted as well as adverse, as long as it is 
unintended and caused by the drug. Depending on the aim of the therapy, a 
pharmacological effect can be the intended therapeutic effect of the drug or a 
side effect. For example, morphinomimetics can in addition to their analgesic 
effect also cause constipation and are therefore sometimes used to treat 
diarrhoea. 
- An "adverse event" is every noxious and unintended effect OCCUlTing during 
or after use of a drug in therapeutic doses. Such events are not necessarily 
caused by the drug. 
- An intoxication is a noxious effect caused by a drug used in higher than 
therapeutic doses, irrespective of the intention of the individual who took the 
overdose. 
In short, there are three groups of adverse effects: 
1. pharmacological adverse reactions 
2. allergic adverse reactions 
3. other idiosyncratic adverse reactions 
1. Pharmacological adverse reactions are effects that are explained by the 
pharmacology of a drug. These effects are therefore predictable. 
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2. Allergic reactions are immunologically mediated reactions, and their 
occurrence depends on the vulnerability of the patient who is using the drug. 
These reactions are therefore unpredictable. 
3. Examples of other idiosyncratic reactions, often on the basis of a metabolic 
aberration or deficiency, are haemolytic anemia caused by certain drugs in 
patients with glucose-6-phosphate dehydrogenase deficiency or peripheral 
neuropathy due to isoniazid in slow acetylators. These reactions are also 
unpredictable unless the status of a patient regarding such types of metabolism 
or deficiencies is known. 
1.2 Why is relatively little known about drug safety before marketing? 
Before a drug is registered, there are four stages of research. First, the drug is 
selected and animal experiments are performed in order to study its 
pharmacological activity and toxicity. Subsequently, phase I clinical trials are 
perfOlmed: healthy volunteers are studied in order to examine the metabolism 
and the phatmacological activity of the drug. Thereafter, phase II clinical trials 
are performed, in which the clinical effect of the drug is studied in small 
groups of selected patients. Then phase III clinical trials are perfOlmed on 
large groups of selected patients. These are mostly prospective, randomized, 
controlled, and double blind. After these studies, a preliminary benefit-risk 
assessment is made. 
In these premarketing studies, the pharmacological adverse effects are 
usually found. The problem, however, is that the drug is usually 
only tested on 1000-2000 people (at the most) 
not tested on elderly people, children and pregnant women 
tested for relatively short periods of use 
tested on people who have only the disease which can be treated with the 
drug and are otherwise without major illnesses 
tested while people are not using other drugs. 
In fact, the real experiment will therefore take place in phase IV, the 
postmarketing phase, in which the drug is used for the first time on a large 
scale and under everyday circumstances. Not until this phase will rare adverse 
effects be found (such as allergic and idiosyncratic reactions) and will more be 
learnt about interactions with other drugs and about the safety of using the 
dl1lg in non-tested groups, such as pregnant women. Not until this phase can 
the value of a drug be assessed during widespread use under everyday 
circumstances, and can a new balance of benefit and risk be made. 
The aim of postmarketing surveillance is: 
- to discover unknown side effects/adverse effects (qualitative aspect) 
16 
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- to measure the incidence of and risk factors for side effectsladverse effects 
(quantitative aspect) 
- to reconsider the benefit/risk ratio of the drug and to compare it to that of 
related drugs 
- to study diagnostic tools for, and mechanisms and prevention of adverse 
effects. 
1.3. Systems and methods for postmarketing surveillance in The 
Netherlands 
There are several systems and methods for postmarketing surveillance in The 
Netherlands. A system is defined as an accessible and ordered data set on the 
level of individual patients, with regards to prescriptions, morbidity, or a 
combination of both. Such systems may vary from drug exposure databases or 
disease registries to a registry encompassing only reported suspected adverse 
reactions. Some of these systems facilitate record linkage. Record linkage 
refers to the linking of morbidity and exposure data in two different databases, 
e.g. on the basis of an individual's social security number. Examples of record 
linkage systems are the Saskatchewan Health Plan in Canada and COMPASS 
in the U.S.A. Both consist of databases which were primarily implemented for 
registration of billing data of health professionals, so called health maintenance 
organisations or other types of health insurance funds. In this way, however, 
they contain data on prescriptions and morbidity. A problem with this type of 
databases is that they were not designed with the intention to perform 
postrnarketing surveillance studies with their data. As a result, these databases 
do not contain infonnation which may be relevant to the outcome of interest 
(such as smoking status). Moreover, some diagnoses are better paid by the 
health maintenance organisations than others, which creates a bias towards the 
registration of such diagnoses. A specific problem of the Medicaid database is 
that it concerns a health care facility for the poor, and therefore is not 
representative of the total population. For a more extensive review of the large 
record linkage systems, the reader is referred to Strom [3]. 
A postrnarketing surveillance method pertains to the way in which the 
relationship between a drug and a disease is studied. Here, we can make use of 
case-reports or case-series when we focus on the clinical description of adverse 
reactions. When studying the frequency of and risk factors for adverse 
reactions according to phannacoepidemiologic standards, a control group is 
important. This can be achieved by perfonning cohort studies, case-control 
studies, or cross-sectional studies. These are the principal methods used in 
epidemiology and phannacoepidemiology. In the following sections a more 
extensive description is given of the most commonly used systems for 
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postmarketing surveillance in The Netherlands, and of the methods which are 
used to this pUlpose. 
1.3.1 Postmarketing surveillance systems in Tlte Netlterlands 
There are several data collections concerning dmg use and morbidity in The 
Netherlands, but only some are useful for pharmacoepidemiologic studies. A 
short descdption of some important systems is given below. 
1.3.1.1. Reporting systems 
1. Netherlands Centre Jor Monitoring oj Adverse Reactions to Drugs 
Since 1963, this centre is located at the Ministry of Health, nowadays in 
Rijswijk. Its monitoring system works with voluntary reporting. Suspected 
adverse reactions to dmgs are directly reported by physicians and pharmacists, 
or via pharmaceutical companies. 
If a suspected adverse reaction is reported, the likelihood of a causal 
relationship between the adverse event and the dmg is examined. Reporting 
physicians are often contacted by telephone and asked for more detailed 
information. Also, in the literature and in the registry itself it is checked 
whether there are more reports of this adverse event on the same dmg. If so, a 
causal relationship might be more likely. When adverse reactions are reported 
to one central agency, it is easier to collect a case sedes of the same adverse 
reaction to a particular dmg. Such series often lead to a publication in a 
medical journal or, if necessary, to further research. Since case reports are 
published in medical joumals, there is feedback of knowledge about adverse 
reactions to other health professionals. By cooperating with centres for 
monitoring of adverse reactions to dmgs from different countries and by 
pooling such data at the World Health Organisation Collaborating Centre for 
International Dmg Monitoring much information is available. 
The centre has recently transferred its reporting scheme to the Netherlands 
Pharmacovigilance Foundation, and changed its name to Dmg Safety Unit. 
2. The Netherlands Pharmacovigilance Foundation (LAREB) 
The Netherlands Pharmacovigilance Foundation (LAREB) started as a regional 
reporting system in Tilburg in 1984, with the idea that if reporting adverse 
reactions to dmgs would be done more frequently, more signals would be 
received, and more information would be obtained from the system. Also, the 
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regionalisation would more easily facilitate feedback to general practitioners 
about drugs and drug use and could contribute to prescription policies within 
the region. Since 1991, the regional registry has expanded to nine regions in 
The Netherlands, with a national coordinating centre. The aim of the 
foundation is to cover the whole country in 12 regions. Local phal1nacists 
collect the infonnation from physicians and patients and in the regional centre 
this is classified as to the probability of the adverse event being an adverse 
reaction to the drug. After evaluation, the final report is fed into the central 
database [4, 5]. The communication lines between reporter and LAREB may 
be quite long, since a physician reports to a phannacist, who in turn reports it 
to the regional REB, from where it goes into the LAREB databank. It is, 
however, also possible to report directly to the LAREB. The advantage of the 
system is, that the reporting phannacist is able to add the prescription history 
of the patient to the report. Since January 1996, the LAREB foundation is 
designated as holder of the national voluntary reporting system in The 
Netherlands. 
Advantages of voluntary reporting systems are: 
I. They are quick, flexible and simple 
2. They are cost-effective 
3. The whole population of users of a drug can be followed during the 
total period of registration of a drug 
4. The voluntary reporting system selects patients who are liable to 
develop idiosyncratic reactions, and acts as a stat1ing point for fiu1her 
research 
Disadvantages of voluntary reporting systems are: 
I. Under-reporting: 
- adverse reactions which are well-known are seldomly reported 
- unknown adverse reactions are not recognized and therefore not 
reported (false-negative) 
2. Reporting bias 
- sometimes a reaction is erroneously seen as an adverse reaction and 
reported (false-positive) 
- publication in the literature leads to more reports on this specific 
adverse reaction 
3. The reporting systems do not give data on the incidence of adverse 
reactions to drugs because of under-reporting and reporting bias, and 
because of the absence of reliable data on drug use. 
Some physicians report adverse reactions to drugs regularly, but most rep0l1 
irregularly or not at all. In a study on anaphylaxis only 8% of the cases of 
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drug-induced anaphylaxis were reported to the Netherlands Centre for 
Monitoring of Adverse Reactions to Drugs [6]. 25 % of physicians reported 
that they had notified an adverse reaction on at least one occasion during their 
working period [7]. Over a period of 3 years, 8% had reported an adverse 
reaction [8]. Only a small number of physicians was unaware of the existence 
of the reporting system. Despite these studies, it is unknown which percentage 
of adverse reactions is reported. This percentage is different for each drug alld 
for each adverse reaction. Therefore, it is impossible to generate incidence data 
or relative risks with reporting data. 
1.3.1.2 Exposure databases 
1. The PHARMO RLS drug database 
The PHARMO RLS drug database was set up by the Department of 
Pharmacoepidemiology and Pharmacotherapy of the University of Utrecht. It is 
a drug database of pharmacy dispensing histories obtained from 27 community 
pharmacies covering all prescription drugs that are dispensed in 6 middle-sized 
Dutch cities [9]. The drug database started in 1985 with one city, and the other 
cities joined the system in subsequent years. Since January I, 1990, all six 
cities are included, which means that the database contains infonnalion on a 
catchment area of approximately 500,000 people. Due to the high standard of 
computerization in the Dutch pharmacies, patient records are readily available, 
and can be anonymously transfelTed to a central database. Since most patients 
ill The Netherlands fill their prescriptions at a single phatmacy, and since all 
pharmacies within these cities are included in the database, almost all 
prescriptions of the people within the catchment area of the database are in the 
database. 
The PHARMO RLS drug database may be linked to the hospital admission 
data ill the six cities as held in a database by the department of Intemal 
Medicine II of the Erasmus University Medical School in Rotterdam. 
Probabilistic linking is done on the basis of patient characteristics (e.g. date of 
birth, gender, and general practitioner) [10]. 
2. OIP 
The Dutch Health Insurance Fund Council owns the "Geneesmiddelen 
Informatie Project", a database with data on the numbers of drugs dispensed by 
phannacies in The Netherlands to about one third of all people in the national 
health insurance system (± 3.2. million). These data are billing data, and 
contain the insurance number of the patient, gender and date of birth, name of 
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the drug, dose, and number of units dispensed, and the date of dispensing. The 
advantage is, that all drugs that are paid for by the insurance are captured in 
this system. The disadvantage of the system is, that it only covers the lower 
socio-economic classes, since only people below a certain income level are 
allowed to participate in the insurance. Also, only drugs dispensed by 
community phannacies are recorded and OTC preparations are not included. 
The database cannot be used for record linkage purposes. 
3.IMS 
Intercontinental Medical Statistics (IMS) is a commercial company, which 
owns several databases. It obtains sales figures on drugs from pharmaceutical 
finns, wholesale distribution, samples of prescribers (general practitioners and 
specialists), and phannacies, using electronic medical files and sales data. The 
disadvantage of sales data from phannaceutical films is that these data do not 
consist of dispensing data. The prescribing data can be quite inaccurate because 
the samples of prescribers are small. There is also a panel of ±150 phannacies 
which deliver their data to IMS. The data from phannacies are anonymized, 
but it is possible to see which drugs were dispensed to one patient at one 
moment in time. The sample of phannacies will be expanded to 300 
phannacies. The indication for use of the drugs in the database is, however, 
unknown. To cope with this problem, IMS supports the "Integrated Primary 
Care Infonnation" (!PCI) database. The data from IPCI are promising, in that 
these contain prescription as well as morbidity data, and the indication for use. 
A more extensive description of the IPCI system is given below. 
Morbidity databases 
Apart from the databases on morbidity mentioned below, the Central Bureau of 
Statistics holds a registry of causes of mortality. Unfortunately, this database is 
of only limited use for phannacoepidemiologic studies, due to strict privacy 
regulations. 
1. The Dutch Centre for Health Care In[ol1llatioll 
The Dutch Centre for Health Care Infonnation has a national registry of 
hospital diagnoses. In this registry, every admission to every general and 
university hospital in The Netherlands is recorded. Diagnoses are coded 
according to the ICD-9-CM. On every admission data on gender, date of birth, 
admission and discharge are recorded, as well as department admitted to, at 
least one principal diagnosis (mandatory) and up to nine additional diagnoses 
21 
Chapter 1 
(optional). The principal diagnosis is usually the disease which has led to 
admission. The additional diagnoses usually consist of events which took place 
during admission (e.g. thrombosis after an operation). The percentage of 
additional diagnoses which is reported is unknown and depends on the hospital 
and the physician. The data are not used for billing pUlposes, and therefore a 
bias towards relatively well-paid diagnoses is not to be expected. 
2. PALGA 
PALGA (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief or 
Pathological National Automated Archive) is the national registIy for 
pathological diagnostic research performed in hospitals or laboratories all over 
the country. It includes all data on all biopsies and specimens taken and 
investigated by pathologists in The Netherlands, and can give information on 
the number of diagnoses of certain diseases that are made by studying cell or 
tissue samples (such as carcinomas), and can link these back to the hospitals 
the data came from. The advantage of the system is that it covers the whole 
countIy, and that all data are collected in the registry, the disadvantage is that 
it only contains data on diseases which have been confirmed by pathological 
investigation. The system is potentially useful and has been used for 
epidemiologic research, but so far not for pharmacoepidemiologic studies. 
1.3.1.1. A database with both data all drug exposure alld morbidity 
IPCI 
Integrated Primary Care Information (IPc!) is a database consisting of data 
from Computerized Patient Records of general practitioners. In order to collect 
the data for the database, general practitioners making use of the Elias database 
system are included, and a Postmarketing surveillance module is added to their 
system. The data on each visit of every patient that are recorded are 
anonymously transferred to IPC!. The data are extensive and include 
complaints of the patient, investigations performed and their resuits, diagnoses 
made and prescriptions of drugs with their indication. Data are transferred 
anonymously to a "gate-keeper", only identifiable by the general practitioner 
via a randomized number. The "gate-keeper" anonymizes the data with regards 
to general practitioner, and these data enter the IPCI database. The database is 
controlled by a SupervisOly Board, which decides on which studies are allowed 
to be performed and which are not. Additionally, all general practitioners 
involved in the system have the right to block data on their patients for an 
intended study. At the moment, about 75 general practitioners, with 
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approximately 200,000 patients in their practices provide data for IPCI. Part of 
these patients rarely visit the general practitioner, which leaves 170,000 to 
180,000 patients with regular contacts in the database. This system is especially 
suited for performing pharmacoepidemiologic studies, since morbidity as well 
as drug data and indications for prescriptions are provided by the database. 
1.3.2. Postmarketiflg methods 
1.3.2.1 Descriptive studies 
1. Case reports 
A case report is a description of a particular adverse event attributed to a 
particular drug. Such a description may be important as a signal, and may 
provide important clinical details, which are useful for the early recognition of 
an adverse reaction. Unless there has been a positive rechallenge or a special 
test (skin test, in vitro test) to prove the association between use of the drug 
and the adverse event, it may be difficult to judge the causal relationship. 
2. Case series 
In a case series, cases of an adverse event attributed to a certain drug are 
collected and described. The causal relationship in a case series, as in a case 
report, is assessed on the basis of individual patient data, and depends on the 
specificity of the clinicopathological pattern, the temporal relationship between 
use of the drug and the start of the event, recovery of a reversible event after 
cessation of the drug and, sometimes, rechallenge with recurrence of the event. 
Also, the use of concomitant drugs and their temporal relationship to the event 
is taken into account. Since several cases can be compared in such a way, it is 
sometimes possible to recognise a particular predisposing factor for a certain 
adverse effect of a drug. In the absence of a control group, case reports and 
case series give no insight into the incidence or relative risk of adverse 
reactions. Moreover, the causal relationship may be difficult to assess. 
1.3.2.2. Epidemiologic study designs 
In epidemiologic study designs, causality is not judged on an individual patient 
level, but depends on the association between events in patients and the drugs 
that are being used within a plausible time window prior to the event. Here, as 
HilI suggested, the strength of the association, the consistency with other 
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investigations, the specificity of the effect, a compatible time sequence, the 
presence of a dose-response relationship, the biologic plausibility of the 
hypothesis, the coherence with what is known of the natural history and 
biology of the disease, experimental evidence, and analogy may be of 
importance [11]. There is discussion about these criteria: a certain exposure 
may have more than one effect (e.g. smoking), and experimental evidence and 
analogies may not always be present, but some, e.g. a compatible time 
sequence, are a sine qua non [12]. 
There are several study designs in pharmacoepidemiology. A short 
description of these methods is given below. 
1. Cohort study 
In a cohort study a group of people is defined according to a certain 
characteristic, and exposure and several variables of interest are measured. 
Then the cohort is followed over time until the end of the study period. In the 
analysis, the proportion of diseased people in the group of exposed people may 
be compared with the proportion in a group of non-exposed people. The 
proportions are expressed as a cumulative incidence, and the comparison with 
the unexposed group is expressed as a relative risk. The frequency of disease 
may also be expressed, however, as an incidence density during exposure, and 
compared to the incidence density during non-exposure as the incidence density 
ratio. 
Strengths of this study design are [13]: 
I. It allows direct measurement of incidence of disease (i.e. adverse 
reactions) in the exposed and nonexposed groups. 
2. It is less liable to selection bias than a case-control study. 
3. The study design is suitable for rare exposure (e.g. new drugs). 
4. It is suitable for studying several adverse reactions concurrently. 
5. If the study is prospective, data on exposure are unbiased, because they 
are assessed before the olltcome occurs. 
6. It can elucidate the temporal relationship between exposure and disease. 
Disadvantages of this study design are: 
I. It can be expensive and time-consuming (because a large group of 
people is needed if the adverse effect is rare, and because exposure has 
to be assessed in the whole study population and not only in a subgroup 
of this population and because usually a long period of follow-up is 
required). 
2. It is sensitive to selection bias (drop-outs, loss to follow-up and 
selection of patients with more severe disease who will lise a newer and 
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"safer" drug for a certain reason, e.g. because their disease is velY 
serious, or because they are prone to certain adverse reactions). 
3. The cohorts are usually too small for the assessment of rare adverse 
reactions. 
4. The validity of the results can be seriously affected by losses to follow-
up. 
2. Case-control study 
In a case-control study, cases are patients with the adverse event. Controls are 
people without the event and may be matched to the cases according to age, 
sex or other variables. With each case, one or several (usually 2 to 4) controls 
are selected. Subsequently, the use of drugs prior to the adverse event is 
assessed. A comparison is made between the group of cases and the group of 
controls with respect to exposure, and expressed as the exposure odds ratio. 
A nice example of a successful case-control study was the study which was 
performed by Herbst et al. on the relationship between the use of 
diethylstilbestrol by the mother and development of clear cell carcinoma of the 
vagina in the daughter [14]. In this study only 8 patients and 32 controls were 
sufficient to show the relationship. 
Strengths of this study design are [15]: 
I. The design is suitable for studying rare adverse reactions. 
2. It is relatively inexpensive compared with other study designs. Exposure 
does not have to be assessed in a whole cohort, but only in a limited 
number of cases and controls. 
3. It may be performed relatively fast with retrospective data. 
4. The design is suitable for studying the relationship with several drugs 
concurrently. 
5. It is particularly well-suited to the evaluation of diseases with long 
latent periods. 
Disadvantages of this study design are: 
I. It is sensitive to bias: 
- information bias, e.g. recall bias: in case of severe disease, cases will 
have a better recall of drug use than healthy controls. 
- selection bias: the selection of cases and controls may be biased and 
related to their exposure status. 
- confounding bias. 
2. The design is not suitable for rare exposure: there is a risk that none of 
the controls will have used the drug of interest. 
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3. With this design it is not possible to directly compute incidence rates of 
disease in exposed and nonexposed individuals, unless the study is 
population based 
4. in some situations, the temporal relationship between exposure and 
disease may be difficult to establish 
3. Cross-sectional study 
In a cross-sectional study, morbidity and exposure are measured at the same 
moment in time. The temporal relationship between exposure and outcome, 
and duration of use are not assessed. Therefore, the cross-sectional design is 
rarely used in phannacoepidemiology. 
4. Case-crossover study 
In a case-crossover study, the patient serves as his or her own control. 
According to some, the best representation of the source population of cases 
are the cases themselves. For a case-crossover study, three points are 
considered pivotal. First, the study must be dealing with an acute adverse event 
as the result of a transient drug effect. Second, the effect period must be 
precisely detennined. Third, one must be able to obtain reliable data on the 
usual pattern of drug exposure for each case, over a sufficiently long period of 
time. The design is useful when studying an acute reaction to a transient drug 
effect, and when the selection of controls is a problem. Also, it is not liable to 
confounding by factors that do not change over time. Although selection of 
controls is not a problem, selection bias of cases may still occur. Periods with 
and without the disease are compared with regards to preceding exposure. This 
design is suitable for studying reversible effects. It is also a suitable design for 
studying life patterns and their relationship to a certain effect (e.g. exertion as 
a trigger of myocardial infarction [16]). 
1.4 The problem of rare, but serious adverse reactions to drugs 
The main problem with all these study designs is, that none of them is suitable 
in case of a rare disease and a rare exposure, which is often the case when 
there is a serious adverse event to a newly marketed drug that needs to be 
investigated. 
In this thesis, a special study design and its usefulness for postrnarketing 
surveillance is investigated: the nationwide population based case-cohort 
design. 
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In this design two postmarketing systems are used: the Dutch Centre for 
Health Care Infomlation (morbidity data) and the PHARMO RLS dlUg 
database (prescription data). The cohort consists of every inhabitant of The 
Netherlands during the slndy period. All patients who have had a certain 
adverse reaction which was reason for admission to a hospital during the slndy 
period are the cases. The reference cohort consists of every inhabitant of the 
catchment area of the PHARMO RLS dlUg database in the same period. 
The idea of case-cohOll slndies is not new: it was ftrst suggested by Kupper 
et at. in 1975 [17], and a method for analysis was, among others, described by 
Prentice in 1986 [18]. The design of a nationwide population based case-cohOll 
slndy with the use of a dynamic population instead of a ftxed cohort, however, 
and its use in postmarketing surveillance, have never been examined before. 
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Scope of the thesis 
The studies in this thesis were initiated by the Drug Safety Unit of the 
Inspectorate for Health Care (the former Netherlands Centre for Monitoring of 
Adverse Reactions to Drugs), when several problems were encountered which 
could not be solved by using data from the voluntary reporting system for 
suspected adverse reactions to dl1lgs. Although such systems are useful for 
generating signals, they do not have the ability to assess the incidences or relative 
risks of adverse reactions because of variable under-repotiing, repotiing biases and 
the absence of reliable data on drug use. When adverse reactions are common, 
these have mostly been quantified already in clinical trials. Rare events, however, 
are mostly encountered for the first time after widespread marketing. 
When the OCCUlTence of rare drug-associated events prevent these from being 
discovered before marketing, there are two commonly used epidemiological 
techniques possible to study their incidence and relative risk in relation to the 
suspected dl1lg. When a dl1lg is scantily used, i.e. the exposure is rare, a cohort 
study may be useful. In this design, a group of users ("cohort") of the suspected 
dl1lg is followed over time, and the nature and frequency of adverse events in this 
cohort are compared to those in a similar group of non-users. This design is not 
suitable for rare adverse events, however. When the drug is often used but the 
disease is rare, it is mostly advised to use a case-control design. In this design, the 
exposure to the suspected dl1lg in a group of patients with the disease ("cases") 
is compared to that in a group of patients without the disease ("controls"). Shortly 
after marketing, however, and sometimes even later, not only the adverse event 
may be rare, however, but also the suspected dl1lg may be rarely used. In this 
thesis we examine whether it is possible to use a case-cohort design under such 
circumstances. 
In this thesis, we focus on two events which are both rare and often caused by 
drugs, i.e. anaphylaxis and agranulocytosis. In chapters 3 and 4, the detailed 
clinical characteristics are given of cases of anaphylaxis to trimethoprim and 
agranulocytosis to trazodone. Subsequently, all reports of anaphylaxis and 
agranulocytosis, as notified to the Dl1Ig Safety Unit since 1974, are presented as 
case-series on anaphylaxis in chapter 5 and on agranulocytosis in chapter 6. In 
chapter 7, the method is described for performing a case-cohort study with the 
data on morbidity and exposure as available in the Netherlands. In chapters 8 and 
9, the case-cohoti studies on anaphylaxis and agranulocytosis are described. In the 
general discussion, chapter 10, we present the advantages and limitations of the 
nationwide population based case-cohort design for pharmacoepidemiology. 
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Summary 
Background: Anaphylactic reactions to co-trimoxazole are often ascribed to 
the sulphamethoxazole component of this antibacterial drug. 
Objective: To determine whether the trimethoprim component can be the 
cause of an anaphylactic reaction. 
Methods: An analysis was made of reports on anaphylaxis attributed to 
trimethoprim, as notified to the Drug Safety Unit of the Dutch Inspectorate for 
Health Care. 
Results: In the period between September 1981 and November 1995, thilieen 
such reports were received. Nine were classified as probable anaphylaxis. Of 
these, the causal relationship between exposure to trimethoprim and 
anaphylaxis was classified as definite in three reports, and as probable in the 
other six. The remaining four reports were classified as possible anaphylaxis. 
In one of these, the causal relationship was classified as definite, and in three 
as probable. 
Conelusion: Although anaphylaxis due to trimethoprim seems to be rare, it 
may be more common than previously thought. Apparently, anaphylaxis to co-
trimoxazole is not always caused by sulphamethoxazole. 
Introduction 
Anaphylactic reactions associated with co-trimoxazole Ca combination of 
sulp~amethoxazole and trimethoprim) are a common phenomenon. Because 
sulphonamides are a frequent cause of allergy, reactions to co-trimoxazole are 
often attributed to the sulphamethoxazole component. Only few data exist on 
allergy to trimethoprim, a dihydrofolic acid inhibitor. Until recently, 
trimethoprim was the antibiotic of first choice in general practice in The 
Netherlands for the treatment of urinary tract infections. 
We describe the case-histories of 13 patients with anaphylactic reactions to 
trimethoprim alone, which were reported to the Drug Safety Unit of the Dutch 
Inspectorate for Health Care CDSU). 
Material and methods 
Between September 1981 and November 1995, 13 cases of anaphylactic 
reactions attributed to trimethoprim were reported to the DSU. In these 13 
cases, repOliing physicians, patients, or patient's relatives were asked about the 
symptoms the patients had experienced, the temporal relationship between 
ingestion of the tablet and the occurrence of symptoms, the duration of 
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symptoms, previous use of tdmethopdm with or without symptoms, known 
allergies and other diseases and other medication used at the time of the 
anaphylactic reaction. 
Classification of anaphylaxis 
In order to classifY repmis as anaphylaxis probable, anaphylaxis possible and 
anaphylaxis unlikely, the method shown in Figure I was used [1,2]. Symptoms 
were recorded in the four main tracts involved in allergic reactions: circulatory, 
respiratory, gastro-intestinal tract, and skin. Circulatory symptoms were: 
hypotension, tachycardia, collapse. Respiratory symptoms were: dyspnoea, 
cough, wheezing, stridor, swelling of uvula or pharynx. Gastro-intestinal 
symptoms were: nausea, vomiting, abdominal cramps, diarrhoea and urge to 
defaecate. Skin symptoms consisted of rash, pruritus, andlor edema (of skin or 
oral or conjunctival mucosa). Symptoms were classified as characteristic of 
anaphylaxis if two or more tracts were involved, except for a combination of 
only the gastro-intestinal tract and the circulatory tract. In the latter case, or if 
only one tract was involved, symptoms were classified as compatible with 
anaphylaxis. The second important feature in distinguishing anaphylactic from 
other adverse reactions is the temporal relationship between ingestion of the 
tablet and the OCCUlTence of symptoms. A time interval of one hour or less was 
considered charactedstic of anaphylaxis. 
Assessment of causal relationship 
The causal relationship between exposure to trimethoprim and anaphylaxis was 
classified as probable if trimethoprim was the only drug used within one hour 
before developing anaphylaxis, or if other drugs were continued without 
recurrence of anaphylaxis (Figure 2). If there had also been a similar reaction 
to inadvelient rechallenge, the causal relationship was classified as definite. 
Also, if the patient had developed similar or milder symptoms to the same 
drug on a previous occasion, the causal relationship was classified as definite. 
The causal relationship between exposure to tdmethoprim and anaphylaxis was 
classified as possible if the patient had been exposed to more than one 
potential calise within one hour before anaphylaxis [1-3). 
Results 
Thirteen patients with an anaphylactic reaction to trimethoprim were reported. 
These consisted of 12 female patients and 1 male patient, aged 22-68 years, 
treated because of a urinary tract infection (n=12) or prostatitis (n=I). 
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Figure 1 Model of classification of anaphylaxis. 
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Figure 2. Model of assessment of causal relationship between exposure to trimethoprim and 
anaphylaxis. 
Causal relationship definite 
+ 
only one drug used within + 
one hour prior to anaphylaxis ' I positive rechallenge I or other drugs continued 
without recurrence 
not perfo nned 
-
Causal relationship pro bable 
more than one drug used + 
within one hour prior to sible Causal relationship pos 
anaphylaxis, and discontinued 
as well as trimethoprim 
Table I shows the relevant characteristics of patients and reactions. 
Nine reports were classified as probable allaphylaxis. Of these, six patients 
experienced gastro-intestinal symptoms, eight had skin symptoms, four had 
respiratory symptoms, and all experienced hypotension. The temporal 
relationship between ingestion of the tablet and the start of symptoms varied 
from 5 to 60 minutes. Of these nine patients all but one (M) were known to 
have used trimethoprim or co-trimoxazole before, three of them reported 
symptoms such as itch or general discomfort on previous exposure, whereas 
four had used the drug before without problems. 
Patient B had a known allergy to allopurinol, acetylcysteine and latex, 
patient C to fe!Tous fumarate, patient F to nitrofurantoin and patient K to 
penicillin. Patient B was known to have Chronic Obstructive Pulmonary 
Disease (COPD). Other medication used by these nine patients were: oral 
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Patient M/F' Age Temporal Tract with Anaphylaxis Causal relationship Rechallenge '" 
(years) relationship symptoms·· 
A F 22 15 min. eire., G,!, skin Probable Definite + 
B F 67 10 min. eire., G-I, skin, resp. Probable Probable + 
C F 30 45 min. eire., G-!, skin Probable Probable 
D F 33 5 min. eire., G-I, skin, resp. Probable Probable 
E F 46 unknown G-!, skin, resp. Possible Probable + :.. ~ F F 68 30 min. eire., skin Probable Probable ~ 
G F 41 <5 hrs. skin, resp. Possible Probable 0 
" " ::t. H M 62 unknown skin, resp. Possible Probable 0 
" ;;: 
J F 34 30 min. eire., G-!, skin Probable Definite + 
" " K F 32 60 min. eire., resp. Probable Probable ~. 
" '" L F 29 3 hrs. skin, resp. Possible Definite + ~ 
M F 37 30 min. eire., skin, resp. Probable Probable 0 c 
" 
N F 37 45 min. eire., G-I, skin Probable Definite is' + 
'" 
"" ;;; 
"" , M = male; F = female "" 
" ... 
eire. = circulatory tract; G-I = gastro-intestinal tract; resp.= respiratory tract; skin = skin and conjunctivae ~ . Reehallenge: + = symptoms after prior or repeated use; - = prior use without symptoms; 0 = no prior or repeated use. 
-
"" ~ 
..,. :::: . 
-
:;; 
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contraceptives (A,C and N), triamterenelhydrochlorothiazide, beclomethasone-
aerosol and salbutamol-aerosol (B). These other drugs had been continued in 
patients B,C and N. 
Four patients were classified as allaphylaxis possible because they had 
symptoms characteristic of or compatible with anaphylaxis, but a temporal 
relationship between exposure and anaphylaxis which was either unknown or 
longer than one hour. 
Patient E reported similar symptoms after previous use of co-trimoxazole. 
Patient L had a known allergy to grass pollen. Three patients (E,G, and L) did 
not use other drugs at the moment of anaphylaxis. Patient H had used 
himethoprim for several days when he experienced asthmatic symptoms on day 
7 and generalized rash on day 8. The temporal relationship with the use of the 
tablets was unknown. He was known to have COPD. Other medication 
consisted of dipyridamole, triamterene/hydrochlorothiazide and 
phenprocoumon, which were all continued. He was treated with 
beclomethasone-ael'Osol, symptoms disappeared in 3-4 days. He had 
experienced an earlier astmatic reaction after use of a beta-blocking agent. He 
had not used trimethoprim before. 
The causal relationship was classified as definite in patients A, J, Land N 
because they had experienced allergic symptoms on more than one occasion 
during use of trimethoprim or co-trimoxazole. Furthermore, other medication 
was continued without problems in all four patients. 
Patient A had taken the first tablet of trimethoprim, and 15 minutes later she 
became dizzy, was shivering, had blue fingers and red eyes, and was 
dyspnoeic. She collapsed in the office of the general practitioner, who found a 
low blood pressure and angioedema. She was treated with clemastine, 
adrenaline and dexamethasone, and she recovered. Previously, she had felt 
unwell during use of co-trimoxazole. 
Patient N developed generalised urticaria, started vomiting and had 
diarrhoea, and became hypotensive (systolic blood pressure 70 rum Hg) within 
45 minutes after use of trimethoprim. She had used trimethoprim before and 
developed pruritus at that time, but did not have a reaction as severe as the 
present one. She recovered quickly after treatment with clemastine and 
prednisolone. 
Patient J developed Quincke's edema, pruIitus, erythema, fecal urge, and 
subsequently collapsed within 30 minutes after using trimethoprim. She had 
used the drug before without problems. She recovered after treatment with 
clemastine and hydrocortisone. In patient J, IgE antibodies against 
trimethoprim were demonstrated. In the other patients, no such tests were 
performed. 
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Discussion 
Thirteen patients with an anaphylactic reaction attributed to trimethoprim were 
reported to the DSU. All patients but one were female, which is probably 
explained by the fact that trimethoprim is often used against urinary tract 
infections, which have a much higher incidence in women than in men. 
Of the thirteen patients, five had known allergies to other substances. We did 
not find evidence in the literature for a cross-allergy between these substances 
and trimethoprim. 
Ten patients reported use of trimethoprim or co-trimoxazole before, five of 
them with symptoms. Unfortunately, most patients did not remember which 
symptoms they had developed, or information was not obtainable. 
Little is known in the medical literature of anaphylactic reactions to 
trimethoprim alone. Although hypersensitivity reactions have been reported, i.e. 
toxic epidermal necrolysis [4], pneumonitis [5], fixed dmg emption [6-8], 
vasculitis [9], and photosensitivity reactions [10], anaphylactic reactions were 
only rarely reported. 
There is only one research group that, in examining reactions to co-
trimoxazole, tried to separate IgE to sulphamethoxazole and IgE to 
trimethoprim. They described methods to detect specific anti-trimethoprim-IgE 
in two patients with an anaphylactic reaction to co-trimoxazole and a positive 
skin prick test or intradermal test with trimethoprim [11]. The authors 
suggested that there seemed to be more than one antigenic determinant on the 
trimethoprim-molecule. Furthermore, they described eight patients with an 
anaphylactic reaction to co-trimoxazole of whom five had specific IgE to 
sulphamethoxazole [12]. One had anti-sulphamethoxazole-lgE with a negative 
RAST-inhibition test and anti-trimethoprim-lgE with a positive RAST-
inhibition test. They also found that there are different epitopes on the 
trimethoprim-molecule, to which specific IgE can be directed [13]. 
Alonso et al. described three patients, two with anaphylactic reactions and 
one with generalized urticaria after use of co-trimoxazole, who had positive 
skin prick tests and rechallenge-tests to trimethoprim and negative skin prick 
and intradelmal tests and rechallenge tests to sulphamethoxazole. No 
significant levels of specific IgE to trimethoprim could be detected [14]. 
Cabaiias et al. reported on a patient with an anaphylactic reaction to co-
trimoxazole, who had a positive skin prick test and specific IgE with a positive 
RAST -inhibition to trimethoprim, while skin prick and intradelmal tests to 
sulphamethoxazole were negative Cas well as in controls) and no IgE against 
sulphamethoxazole could be found. Oral challenge with sulphamethoxazole was 
negative, but with trimethoprim this was not performed because of the lisk 
[15]. 
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In one of our reported patients (patient J) anti-trimethoprim-IgE was 
measured and detected, using two different preparations of trimethoprim. 
No data exist on the incidence of anaphylaxis to trimethoprim compared to 
co-trimoxazole. In a previous study by the Drug Safety Unit [2] 12 
anaphylactic reactions were reported to co-trimoxazole (4 probable and 8 
possible anaphylaxis) and 11 to trimethoprim (4 probable and 7 possible 
anaphylaxis). Unfortunately however, reporting bias and the absence of reliable 
drug utilisation figures make it difficult to assess the incidence rates of these 
adverse effects. 
In conclusion, anaphylactic reactions to co-trimoxazole should not be attributed 
too easily to the sulphamethoxazole-component, since anaphylaxis to 
trimethoprim may not be as uncommon as previously thought. 
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AgranulocytosiS probably induced by trazodolle 
We report on a patient with agranulocytosis probably induced by trazodone, an 
antidepressant which is chemically different from other antidepressants. With 
the exception of priapism [I], it has a more favourable adverse reaction profile 
than conventional antidepressants [2]. 
Mr. A, a 40-year-old man, was admitted to the hospital because of perianal 
furuncles, which had developed five days earlier. For one week there was 
malaise, an unproductive cough, and gingivitis for which he had been treated 
with 500 mg paracetamol once, sodium perborate mouthwash, and a course of 
doxycycline. He had no relevant medical history. He had been using trazodone 
for a month until one week before admission, in a dose of up to 100 mg/day 
because of depression. He had not been exposed to other drugs or chemicals. 
On examination he had a normal temperature, mild gingivitis, inguinal 
lymphadenopathy, and several perianal furuncles. Further physical examination 
was unremarkable. Hematology profile was normal with the exception of an 
erythrocyte sedimentation rate of 30 mmlhour (normal range 2-10), leukocyte 
count of 3.7 x 10'/1 (normal range: 4.0-10.0) and the differential cell count: 
74% lymphocytes of which several were atypical, 25% monocytes and 1% 
eosinophils. Electrolytes and renal and liver functions were normal. Urinalysis 
showed mild proteinuria and 5-9 leukocytes and 15-19 erythrocytes per high 
power field. No bacteria were demonstrated, and a urinary culture was sterile. 
Aspartate aminotransferase was 300 IV/ml (normal: 0-200). Antinuclear factor, 
Rose-Waaler test, Paul Bunnell and autoantibodies against granulocytes and 
platelets were negative. A bone marrow biopsy showed a normal 
erythropoiesis, megakaryopoiesis and myelopoiesis; however, the latter with a 
slight shift to the left. A culture of the pus of the furuncles yielded a 
staphylococcus aureus. The patient was isolated for two days and treated with 
flucloxacillin. No corticosteroids were given. At discharge, four days after 
admission, leukocytes had risen to 8.4 x lO'n (62 % neutrophils) and 
erythrocyte sedimentation rate had decreased to 19 mmnlOur. The urinalysis 
results were normal, as were results of routine blood examinations performed 
one week after discharge, and repeated three months later. 
In this patient no potential cause of agranulocytosis was found other than 
trazodone. All other drugs were started after the first symptoms had developed. 
In view of the temporal relationship, the rapid recovery after discontinuation, 
and the absence of other causes, trazodone appears to be causative. We could 
not find any report attributing agranulocytosis or leukopenia to trazodone in 
the literature, but a decrease in erythrocytes has been attributed to trazodone 
occasionally [3]. The manufacturer had received two additional reports on 
agranulocytosis to trazodone. 
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Drug-associated anaphylaxis: 20 years oj reporting in The Netherlands 
Summary 
Background Since 1963, the Drug Safety Unit of the Dutch Inspectorate for 
Health Care (DSU) holds a voluntary reporting system. 
Objective To analyse all reports received in the years 1974 through 1994, 
registered as anaphylaxis or as a diagnosis that could contain cases of anaphylaxis. 
Methods All reports were classified as probable or possible anaphylaxis 
according to previously described criteria and the causal relationship between 
exposure and anaphylaxis was assessed. 
Results Nine hundred and ninety-two reports possibly concerning anaphylaxis 
were received from 1974 through 1994. Fifty-six were unclassifiable. The 
remaining 936 reports concerned 326 men and 610 women. Three hundred and 
forty-five reports were classified as anaphylaxis probable, 485 as anaphylaxis 
possible, and 106 as anaphylaxis unlikely by previously specified criteria. Drugs 
fi'equently associated with anaphylaxis (causal relationship certain or probable) 
were: glafenine (326 reports classified as anaphylaxis probable or possible), 
combination preparations with (propy)phenazone or propyphenazone/phenacetine 
(39), diclofenac (30), dextran (20), ibuprofen (14), floctafenine (12), allergen 
extracts (12), sulphamethoxazole with trimethoprim (12), and ttimethoprim (II). 
There is probably substantial under-reporting as well as reporting bias in these 
data. Furthemaore, many reports were classified as possible and not as probable 
anaphylaxis because the temporal relationship was unknown or not reported. 
Conelusion Drugs that caused anaphylaxis most frequently were glafenine, 
NSAID and certain antibiotics. Data from a voluntary reporting system such as 
the DSU are valuable as an early warning system for drugs that may induce 
anaphylactic reactions. 
Introduction 
Anaphylaxis is usually defined as an acute allergic reaction that results from the 
release of phamaacologically active mediators from tissue mast cells and 
peripheral blood basophils. IgE antibodies bind to mast cells, cause activation and 
subsequent degranulation. An anaphylactoid reaction is a similar reaction, but not 
mediated by IgE antibodies, and not requiring previous exposure. Since both 
syndromes are clinically indistinguishable, in this slndy we used the tenn 
anaphylaxis to describe both [1,2). 
Drug-induced anaphylaxis is a very serious adverse event, and may be fatal. 
Data regarding the incidence of drug-induced anaphylaxis are limited. Antibiotics 
and radiocontrast agents seem to be the most common causes of serious 
anaphylaxis, with rates of about 1 in 5000 exposures [2). Drugs which cause 
anaphylaxis are mainly known from case reports and some small case series. 
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Therefore, we present an analysis of all 992 reports of drug-associated anaphylaxis 
received by the Drug Safety Unit of the Dutch Inspectorate for Health Carc 
(DSU) from 1974 through 1994 and a review of the literature. 
Material and methods 
Setting 
Since 1963, the DSU holds a voluntary reporting system, which has comparable 
procedures to the Yellow Card System in the United Kingdom. The number of 
reported reactions per year has grown to 1780 in 1994. Reports are made by 
physicians (mostly general practitioners). A small number ofrepOlis are made by 
a phannacist. In this case, the prescribing physician is contacted for more detailed 
infonnation regarding the adverse event. 
In this study, the reports received from 1974 through 1994 were analysed. All 
reports registered as anaphylaxis, anaphylactic shock or reaction, anaphylactoid 
shock or reaction, allergic reaction, face oedema, and periorbital or eyelid oedema 
were included. Also included were combinations of skin reactions (such as rash, 
urticaria, angioedema or pruritus) with respiratory tract reactions (such as 
bronchospasm, dyspnoea, laryngeal edema or stridor) or with cardiovascular 
reactions (such as hypotension, syncope, circulatory failure or collapse) or with 
death, and combinations of respiratory reactions with death. All reports were 
classified according to probability of anaphylaxis by the criteria shown in Figure 
I and described earlier [3]. The reports had to contain details on gender and date 
of birth of the patient, and had to be confinned by a medical practitioner in order 
to be classifiable. 
Symptoms characteristic of anaphylaxis were symptoms Ollt of two or more of 
the following four systems except for a combination of only the cardiovascular 
and the gastro-intestinal system: 
I Cardiovascular system 
2 Respiratory system 
3 Skin and conjunctiva 
4 Gastro-intestinal system (e.g. nausea, vomiting, diarrhoea, abdominal pain) 
Symptoms compatible with -but not characteristic of- anaphylaxis were 
symptoms out of only one of the above mentioned systems (with the exception 
of the gastro-intestinal system) or a combination of cardiovascular and gastro· 
intestinal symptoms. Otherwise, symptoms were not compatible with anaphylaxis 
[3]. 
The temporal relationship was considered as characteristic of anaphylaxis if the 
reaction occurred within one hOllr after exposure to the callsative agent, or was 
described as "shortly" or "immediately" after exposure. 
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. Figure 1 Model of classification of anaphylaxis. 
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Assessmellt of causal relatiollship 
The causal relationship between exposure to the drug and anaphylaxis was 
classified as "causal relationship probable" if the patient had been exposed to one 
suspected cause within one hour before developing anaphylaxis, and as "causal 
relationship certain" if, in addition, there had been a positive reaction to 
rechallenge. The classification "causal relationship possible" was used if the 
patient had been exposed to more than one potential cause within one hour before 
anaphylaxis. The classification "causal relationship unlikely" was used if the 
temporal relationship was incompatible, i.e. in cases in which the exposure did not 
precede the reaction ( challenge), in which discontinuation was not followed by 
recovery of a reversible event (dechallenge), or in which continuation or 
readministration (rechallenge) did not cause a relapse. 
Results 
Nine hundred and ninety-two reports were analysed, of which 56 were 
unclassifiable because of lack of data. The remaining 936 reports concerned 345 
cases in which anaphylaxis was probable, 485 cases in which anaphylaxis was 
possible, and 106 cases in which anaphylaxis was unlikely. 
Symptoms mentioned in the reports classified as probable and possible 
anaphylaxis are summarized in Table 1. 
Descriptions of reports concerning age and gender, the temporal relationship 
between exposure and outcome, where and how patients were treated and patient 
recovery are summarized in Table 2. In those reports classified as probable 
anaphylaxis, the temporal relationship between exposure and outcome was less 
than one hour in all reports. Mostly, reports were classified as possible and not 
as probable anaphylaxis because the exact temporal relationship between exposure 
and outcome was not reported or unknown, which was the case in 332 out of 485 
reports (68.5%). 
Of the 830 reports of probable or possible anaphylaxis, 206 patients (24.8%) 
were admitted to a hospital or treated in the accident and emergency department, 
441 (53.1%) were treated by the general practitioner, or not treated at all, and in 
117 patients (14.1%) anaphylaxis occurred inside a hospital. 
Treatroent consisted mostly of adrenaline, corticosteroids, or antihistamines, or 
a combination of two of these or all three. In 400 reports, treatroent was unknown 
or not mentioned. 
Of 345 patients with probable anaphylaxis, two recovered with irreversible 
damage (one vascular occlusion and one myocardial infarction), and 14 people 
died due to the anaphylaxis. Of 485 patients with possible anaphylaxis, two still 
had exanthema at the time of reporting, two recovered with irreversible damage 
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Table 1. Symptoms mentioned in the reports classified as probable and possible anaphylaxis (% 
of total in brackets). 
Symptom Anaphylaxis Anaphylaxis Total (n~830) 
probable possible 
(n~345) (n~485) 
Collapse or immeasurable blood pressure 142 (41.2%) 178 (36.7%) 320 (38.6%) 
Blood pressure < 100 mm Hg and no 54 (15.7%) 27 (5.6%) 81 (9.6%) 
collapse, or hypotension during surgery 
Blood pressure >100 mm Hg, but lower 6 (1.7%) 6 (1.2%) 12 (1.4%) 
than nonnal (hypertensive patient) 
Blood pressure lowered, exact value 49 (14.2%) 35 (7.2%) 84 (10.1%) 
unknown 
Blood pressure not lowered 27 (7.8%) 28 (5.8%) 55 (6.6%) 
Blood pressure unknown 67 (19.4%) 211 (43.5%) 278 (33.5%) 
Urticaria 96 (27.8%) 117 (24.1%) 213 (25.7%) 
Erythema or generalised flushing 181 (52.5%) 165 (34.0%) 346 (41.7%) 
Ailgioedema 145 (42.0%) 206 (42.5%) 351 (42.3%) 
Pruritus 124 (35.9%) 113 (23.3%) 237 (28.6%) 
Other type of skin reaction 10 (2.9%) 18 (3.7%) 28 (3.4%) 
Skin reaction of unknown type 1 (0.3%) 4 (0.8%) 5 (0.6%) 
No skin reaction 12 (3.5%) 16 (3.3%) 28 (3.4%) 
Skin reaction unknown 23 (6.7%) 120 (24.7%) 143 (17.2%) 
Edema of the glottis 23 (6.7%) 23 (4.7%) 46 (5.5%) 
Bronchospasm 66 (19.1%) 39 (8.0%) 105 (12.7%) 
Laryngeal spasm or larygeal edema 13 (3.8%) 3 (0.6%) 16 (1.9%) 
Dyspnoea, but type unknown 101 (29.3%) 79 (16.3%) 180 (21.7%) 
No dyspnoea 42 (12.2%) 28 (5.8%) 70 (8.4%) 
Dyspnoea unknown 106 (30.7%) 316 (65.2%) 422 (50.8%) 
Nausea/vomiting 70 (20.3%) 49 (10.1%) 119 (14.3%) 
Diarrhoea/fecal urge 45 (13.0%) 24 (4.9%) 69 (8.3%) 
Abdominal spasm/stomach pain 33 (9.6%) 20(4.1%) 53 (6.4%) 
No gastro-intestinal symptoms 11 (3.2%) 7 (1.4%) 18 (2.2%) 
Gastro-instestinal symptoms unknown 205 (59.4%) 366 (75.5%) 571 (68.8%) 
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Table 2. Descriptives. 
Gender 
Age (yr)' 
Temporal 
relationship 
Admission 
Treatment 
Recovery 
male/female 
males 
females 
< 15 minutes 
15 - 30 miu. 
30 - 60 min. 
"within 1 hour" or "directly after 
administration" 
1 - 2 hours 
> 2 hours 
not reported or unknown 
admitted to hospital 
treated in A&E" 
treated by GP'" or not treated 
during admission 
not reported or unknown 
adrenaline 
corticosteroid drug 
antihistaminic drug 
adrenaline and corticosteroid drug 
adrenaline and antihistaminic drug 
corticosteroid and antihistaminic drug 
adrenaline. corticosteroid and antihistaminic 
drug 
olher combination 
no treatmcnt 
treatment unknown or not mentioned in 
report 
complete 
incomplete or with irreversible damage 
died 
unknown 
median age (25%-75%) 
Anaphylaxis 
probable (0=345) 
1241221 
47 (35-61) 
44 (31-60) 
149 (43.2%) 
88 (25.5%) 
41 (11.9%) 
67 (19.4%) 
102 (29.6%) 
7 (2.0%) 
158 (45.8%) 
54 (15.7%) 
24 (7.0%) 
5 (1.4%) 
22 (6.4%) 
31 (9.0%) 
15 (4.3%) 
12 (3.5%) 
45 (13.0%) 
19 (5.5%) 
56 (16.2%) 
26 (7.5%) 
114 (33.0%) 
319 (92.5%) 
2 (0.6%) 
14 (4.1%) 
10 (2.9%) 
A&E = Accidents and Emergency department, admission <0.5 day 
GP = General Practitioner 
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possib e (0=485) 
176/309 
45 (33-60) 
48 (34-60) 
40 (8.2%) 
21 (4.3%) 
17 (3.5%) 
22 (4.5%) 
29 (6.0%) 
24 (4.9%) 
332 (68.5%) 
90 (18.6%) 
7 (1.4%) 
283 (58.4%) 
63 (13.0) 
42 (8.7%) 
4 (0.8%) 
20 (4.1%) 
31 (6.4%) 
11 (2.3%) 
12 (2.5%) 
39 (8.0%) 
11 (2.3%) 
31 (6.4%) 
40 (8.2%) 
286 (59.0%) 
444 (91.5%) 
4 (0.8%) 
7 (1.4%) 
30 (6.2%) 
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(one myocardial infarction and one suffered a cardiac atTest and had post-
resuscitation rib fractures and amnesia), and 7 died. The drugs responsible for 
fatal anaphylaxis were: radiocontrast agents (8), dextran (3), glafenine (2), 
immunotherapy for allergy (2), protamine (I), penicillin (I), tetracosactide (I), 
metoprol01 (1), erythromycin (I) and butylscopolamine with metimazole (I). 
One hundred and ninety-nine out of 345 patients with probable anaphylaxis had 
used the causative drug before, and of them 89 had had a similar reaction to the 
drug previously, or had a positive rcchallenge to the drug. The reactions occurring 
previously mostly consisted of a less serious reaction (e.g. erythema or urticaria) 
than anaphylaxis, but sometimes they consisted of a full-blown anaphylactic 
reaction. Additionally, two patients experienced anaphylaxis during 
immunotherapy for allergy. Of the 485 patients with possible anaphylaxis, 230 
had used the drug before, and of these 94 had had a previous reaction, or had a 
positive rechallenge. Also, two additional patients experienced anaphylaxis during 
immunotherapy for allergy. Of the reports of probable anaphylaxis, 26 patients 
had never used the drug before, and in 120 reports this was unknown. For the 
reports of possible anaphylaxis these figures were 27 (never used before) and 228 
(unknown). 
In the reports classified as probable anaphylaxis, the causal relationship between 
exposure and anaphylaxis was certain in 77 reports, probable in 254 reports, 
possible in 13, and unlikely in I (Table 3). In the reports classified as possible 
anaphylaxis, the causal relationship between exposure and anaphylaxis was certain 
in 80 reports, probable in 362 reports, possible in 42, and unlikely in I. 
Table 3. Classification of anaphylaxis and causal relationship, 
Anaphylaxis probable Anaphylaxis possible Total 
Causal relationship certain 
Causal relationship probable 
Causal relationship possible 
Causal relationship unlikely 
Total 
77 
254 
13 
345 
80 
362 
42 
485 
157 
616 
55 
2 
830 
The most frequent causes of drug-associated anaphylaxis are specified in Table 
4 for the reports classified as probable and possible anaphylaxis. 
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Table 4. Causes of drug-associated anaphylaxis with a causal relationship certain or probable. (Number 
of deaths between brackets). 
Drug Ana~hYlaxis Anachylaxis Total 
Erobab e {n=331} Eossib e (n=442): (n~773) 
Glafenine 146 (2) 180 326 (2) 
Propyphenazone/paracetamol, 17 20 37 
propyphenazonerchenacetine or 
propyphenazone carzenide 
Diclofenac 12 18 30 
Dextran 9 (2) 11 (1) 20 (3) 
Ibuprofen 5 9 14 
Floctafenine 9 3 12 
Allergen extracts 7 (2) 5 12 (2) 
Sulphamethoxazole with trimethoprim 4 8 12 
Trimcthoprim 4 7 11 
Amoxycillin 6 3 9 
Blood expanders (gelatine) 3 5 8 
Naproxen 2 6 8 
Mebhydroline 2 4 6 
Polidocanol 5 6 
Cimetidine 2 4 6 
Paracetamol +/- coffein 1 5 6 
Ranitidine 2 3 5 
Tolmetine 3 2 5 
Fytomenadione 2 2 4 
CWorhexidine 5 2 7 
Furoxone 4 4 
Nitrofurantoin 4 4 
Ketocollazoie 2 2 4 
Atracurium 2 2 4 
Amidotrizoic acid· 3 (2) 4 (2) 
Omeprazole 3 3 
Metimazolelhutylscopoiamine 3 3 
Domperidone 3 3 
Tetracosactide 2 1 (1) 3 (1) 
Indomethacin 2 3 
Acetylsalicylic acid 2 3 
Combinations with ergotamine .. 2 3 
Expectorants, combination preparations 2 3 
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Drug Anaphylaxis Anaphylaxis Total 
probable en 331) possihle (n 442) (0 773) 
Acetylcystein 3 3 
Terfenadine 2 3 
Metrizoic acid' 2 (2) 3 (2) 
Patent blue 2 3 
Metimazole/pitophenone/phenpiveriniumbromide 2 (I) 2 (I) 
Vitamin B complex 2 
Heparin 2 2 
Phenazone/phenazonesalicylate/coffeinlkinine 2 2 
Ticlopidine 2 2 
Parenteral Ferri preparation 2 2 
Urapidil 2 2 
Captopril 2 2 
Enalapril 2 2 
Hymochorothiazide with potassium sparing drugs 2 2 
Terbinafine 2 2 
Methoxsalene 2 2 
Ergometrine 2 2 
Medroxyprogesterone 2 2 
Nalidixinic acid 2 
Pipemidinic acid 2 2 
Amoxycillin with clavulanic acid 2 
Piroxicam 2 2 
Ketoprofen 2 
Prilocain 2 
Bromocriptine 2 2 
Maprotiline 2 2 
Mefloquine 2 
Bromhexine 2 2 
Promethazine 2 2 
Protamine I (I) 2 (I) 
loxitalamic acid' 2 (I) 2 (I) 
Diagnostic radiopharmaca 2 2 
Miscellaneous {all mentioned once} 41 (2) 76 (2) 117 (4) 
Total 331 442 773 
= radiocontrast agents 
= ergotamine/cyclizine/coffeinor ergotamine/cyc1izine or ergotamine/caffein 
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The causative drugs are shown for those reports in which the causal relationship 
was classified as certain (n=157) or as probable (n=616). Glafenine was the drug 
most frequently associated with anaphylaxis, followed by combination 
preparations of propyphenazone, phenazone and phenacetine, non-steroidal anti-
inflammatory drugs (NSAID) (diclofenac, ibuprofen, and naproxen), dextran, 
floctafenine, allergen extracts, and antibiotics (trimethoprim with or without 
sulphamethoxazole, amoxycillin, furoxone, and nitrofurantoin). 
Discussion 
This study describes 992 cases of drug-associated anaphylaxis which were 
reported during a period of good 20 years. This amounts to a mean of ± 50 
reports of drug-associated anaphylaxis per year in a country with 13,000,000 to 
15,000,000 people in those years. Probably, the frequency of drug-associated 
anaphylaxis is much higher, as even though anaphylaxis is a serious adverse 
reaction, under-reporting is substantial. In two studies perfonned by the authors 
only 8% [3] and 4% [4] of cases of drug-associated anaphylaxis had been reported 
to the DSU. The clinical pattern of anaphylaxis in our study is in line with the 
medical literature on this topic. Because serious reactions are more readily 
reported, however, the prevalence of serious symptoms in our study (e.g. shock) 
may be over-represented. Of 773 reports of drug-associated anaphylaxis with a 
causal relationship certain or probable, 326 were associated with glafenine, the 
next most frequently reported drugs being combination preparations of 
paracetamol and (propy)phenazone and phenacetine (45 reports), diclofenac (30 
reports), and dextran (20 reports). The large number of reports on glafenine is 
especially important in view of the small sales figures the drug had in The 
Netherlands when compared to the other analgesics and NSAID. Part of this is 
probably due to reporting bias; part, however, reflects the relatively high 
incidence of glafenine-associated anaphylaxis, as was found in a nationwide study 
perfonned in The Netherlands [3]. Glafenine is an analgesic drug, which was 
withdrawn worldwide in 1992 [5]. 
Other drugs often reported as a cause of anaphylaxis were ibuprofen, 
floctafenine, allergen extracts, the combination of sulphamethoxazole with 
trimethoprim or trimethoprim alone, amoxycillin, blood volume expanders, 
naproxen, mebhydroline, polidocanol, cimetidine, ranitidine, and tolmetine. Other 
antibiotics than the aforementioned were less often reported, partly due to the fact 
that most reports were made by general practitioners, and probably partly due to 
under-reporting. 
Of 345 reports classified as probable anaphylaxis, symptoms developed later 
than 30 minutes after exposure in 41 reports (11.9 %). These data support the 
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policy of observing a patient for at least one hour after administration of antigen 
during trealroent with immunotherapy for allergy. 
Out of 830, 21 patients died, and 6 suffered irreversible damage due to the 
anaphylaxis, stressing the severity of this adverse event. 
Unfortunately, because the temporal relationship was not explicitly stated, a 
relatively large number of reports did not contain enough information for 
classification as probable anaphylaxis. 
Most publications on drug-associated anaphylaxis consist of case-reports. 
Anaphylaxis associated with almost all of the 17 most frequently reported drugs 
in Table 4 was described in the literature. Examples are anaphylaxis associated 
with glafenine [6-11], paracetamol [12-14], diclofenac [15-17], dextran and other 
blood volume expanders [18-20], ibuprofen [21], naproxen [22], cimetidine [23-
24], ranitidine [25] and tolmetine [26-30]. The DSU published case reports or 
case series on anaphylaxis associated with glafenine [3,4,31], paracetamol [32], 
f10ctafenine [33], polidocanol [34], cinoxacin [35], isoflurane [36], chlorhexidine 
[37], bromhexine [38], and ketoconazole [39]. 
Three studies were performed on drug-associated anaphylaxis with the use of 
reporting systems, two focussing on plasma expanders [40,41], and one on 
NSAID's [42]. In the Swedish study [40] all reports on dextran-induced 
anaphylaxis during the period 1970-1979 were studied. Since 1974' reporting of 
fatal and serious adverse reactions has been mandatory in Sweden. The authors 
estimated the incidence of severe anaphylaxis per unit administered to be 0.013% 
for dextran 40 and 0.025% for dextran 70. In the German study [41], during the 
period 1969 to 1976 all reports on transfusion emergencies following the 
administration of colloid plasma expanders dextran, gelatin and starch were 
studied. Since in Germany reporting of adverse reactions to drugs was not 
mandatory, an incidence could not be estimated. The study on NSAID [42] was 
performed with data from the voluntary Adverse Drug Reaction Reporting System 
(ADRRS), a system administered by the American Academy of DClmatology. 
There were four reports of drug-associated anaphylaxis during the period 
December 1980 through July 1983, all associated with zomepirac. 
Only a small number of epidemiological studies on drug-associated anaphylaxis 
have been performed [43-46], probably because anaphylaxis is a rare adverse drug 
reaction. All patients admitted with a clinical diagnosis of anaphylaxis, 
anaphylactic reaction or anaphylactic shock at the Mayo Clinic and affiliated 
hospitals were studied during a 3.5 year period [43]. Only 23 ont of 179 cases of 
anaphylaxis were attribnted to drugs in this study. In a study performed by 
Rudolph et al. [44], reactions to penicillin trealroent in patients visiting venereal 
disease clinics were studied. The incidence of anaphylaxis among these patients 
was 0.04% in 1969, with the incidence of moderate to severe anaphylaxis being 
0.018% among treated patients. From data of this survey and previous surveys 
conducted in 1954, 1959 and 1964 combined, the incidence of moderate to severe 
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anaphylaxis was estimated at 0.025% of treated patients. The authors estimated 
the fatality rate to be 0.00 I % of treated patients. In a study performed by Porter 
and Jick [45] adverse reactions to drugs during hospitalisation at selected medical 
wards in the U.S.A. and several other countries were studied. Drug-associated 
anaphylaxis was reported in 0.04% of all patients (12 out of 32,812 patients, 9 
following intravenous therapy). In a Danish study [46], during a 13-year period 
only 20 cases of anaphylaxis were found in the catchment area of one specific 
hospital, of which 10 were caused by drugs (7 by penicillin and 3 by aspirin). 
None of these cases were reported to the national health authorities. 
Some multi-centre trials have been performed, examining the incidence of 
anaphylaxis due to plasma expanders [47-50] and penicillins [51], the more 
frequent causes of anaphylaxis. Ring and Messmer [47] estimated the incidence 
of anaphylaxis at 0.033% of units of colloid solutions used in general, of which 
0.069% for dextran 60175, 0.007% for dextran 40, and 0.115% for gelatin. In a 
multicenter prospective study on polygeline [48] only one patient (0.09%) 
developed systemic anaphylaxis. In a prospective study on dextran 70 induced 
anaphylaxis [49] 14 females experienced anaphylaxis (0.24%). In a prospective 
study oil plasma substitutes [50] 43 out of 19,593 patients developed an 
anaphylactoid reaction (0.219%). The incidence of anaphylaxis due to gelatins was 
0.345%, due to dextrans 0.273%, due to albumins 0.099%, and due to amidons 
0.058%. Unfoliunately, the exclusion criteria applied to the cases were not 
applied to the control group. 
One of the most frequently studied drugs causing anaphylaxis is penicillin. In 
a review at1icle Weiss and Adkinson [52] reported the frequency of allergic 
reactions to penicillin to vary from 0.7% to 8% of treatment courses in various 
studies. According to Idsoe et al. [53] the frequency of anaphylaxis due to 
penicillin varies from 0.0 I % to 0.035%. In a study performed by the International 
Rheumatic Fever Study Group [51]1790 patients from II countries were enrolled 
in a prospective study to determine the incidence of allergic reactions to monthly 
intramuscular benzathine penicillin. Four patients experienced anaphylaxis, which 
means a case incidence of 0.2% and an injection frequeny of 0.012%. One of 
these four patients died (case fatality rate 0.05%). 
Radiocontrast materials are also well-known causes of anaphylaxis. Siegle et 
al. examined a group of patients who previously reacted with anaphylaxis to 
intravenously administered ionic high-osmolar contrast material. During the study 
291 patients received iohexol, of whom 16 (5.5%) experienced anaphylaxis. It 
appeared that the more serious the prior reaction, the higher the rate was of repeat 
reactions [54]. 
In a study by Matloff et al [55] all systemic reactions during one year due to 
immunotherapy were included. Out of 27,806 injection visits, 143 resulted in 
systemic reactions (0.51%), of which 17% needed adrenaline therapy. 
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Our study shows the overview of reports of drug-associated anaphylaxis in The 
Netherlands in the past 20 years. For some of the drugs this adverse reaction was 
unknown at the time of reporting. Most of these associations have been published 
by the DSU. In some (e.g. glafenine), data of the DSU have been used as a signal 
for a high frequency of adverse reactions. Because of the low frequency of drug-
induced anaphylaxis, this adverse reaction is hard to investigate, which the above 
overview of the literature shows. Prospective studies are vety difficult to perform. 
Also, these are limited to certain classes of drugs, as e.g. drugs which are used 
relatively frequently in an easily accessible population, as e.g. blood volume 
expanders which are exclusively used in a hospital setting. Therefore, a repmiing 
system for adverse reactions as the DSU remains essential for signal generation 
of unknown and unexpected adverse reactions to drugs. For a reporting system to 
function properly, several items are of importance. First, doctors should repmi all 
serious and unexpected adverse reactions. Second, the possibility of obtaining 
further details from reporters is essential. Third, all unknown or unexpected 
adverse reactions should be reported in the medical literature. 
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Summary 
In.this descdptive study, all 425 reports were included conceming drug-associated 
agranulocytosis as registered between 1974 and 1994 in the files of the Drug 
Safety Unit of the Dutch Inspectorate for Health Care. All reports were analysed 
as to the probability of agranulocytosis or neutropenia according to previously 
defined criteria. Subsequently, the causal relationship between exposure and 
outcome was assessed. It concemed 149 men and 271 women. 112 repOlis were 
unclassifiable because age, gender or total number of leukocytes at the time of 
reaction were unknown. In 100 reports agranulocytosis was probable, in 78 
possible, in 8 reports neutropenia was probable, in 20 reports neutropenia was 
possibe, and in 107 agranulocytosis or neutropenia were unlikely. In the 13 
reports of probable agranulocytosis or neutropenia with a certain causal 
relationship, causative drugs were cimetidine, dipyrone, sulphasalazine, 
methyldopa, spironolactone, propylthiouracil (2), thiamazole, sulphamethoxazole 
with trimethoprim, gentamicin, a combination preparation containing 
aminophenazone, benzylpenicillin and indomethacin. The individual drugs most 
often reported to cause agranulocytosis or neutropenia were: dipyrone (19), 
miansedne (15), sulphasalazine (13), sulphamethoxazole with trimethoprim (11), 
the group of penicillins (9), cimetidine (8), the thiouracil derivatives (8), 
phenylbutazone (8), and penicillamine (8). Agranulocytosis is a serious and fairly 
frequently repOlied adverse reaction. The reporting system of the Drug Safety 
Unit can be used very well for signal generation conceming adverse reactions to 
drugs. 
Introduction 
Although agranulocytosis has many causes, the proportion attributable to drugs 
is substantial. Agranulocytosis was first associated with drugs by Madison and 
Squier [1]. Knowledge as to which drugs cause agranulocytosis is mainly based 
on case-reports. As agranulocytosis is such a rare adverse reaction, only few 
epidemiologic studies have been performed on this subject. However, it is a very 
sedous reaction, with a case-fatality rate of up to 32% [2]. It is therefore velY 
important to know which drugs are capable of inducing agranulocytosis. 
The Drug Safety Unit of the Dutch Inspectorate for Health Care (DSU) received 
425 reports of drug-associated agranulocytosis, neutropenia or leukopenia in the 
years 1974 to 1994. In this paper we give a description of these reports and 
discuss the proposed mechanism of agranulocytosis of each drug. 
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Material and methods 
The DSU mns a voluntary reporting scheme for suspected adverse reactions to 
drugs. RepOlis of the years 1974 to 1994 were used for this study. All reports 
with a diagnosis of agranulocytosis, granulocytopenia, neutropenia, leukopenia, 
pancytopenia, bone malTOW aplasia or depression, and myeloproliferative disorder 
were analysed according to a two-step procedure. 
Firstly, every repOli was classified by the first author as to probability of 
agranulocytosis and the probability that agranulocytosis was caused by a dmg 
according to the following criteria: 
In order to be classifiable, age and gender of the patient, and the number of 
leukocytes during the adverse reaction had to be known. Fmihennore, if the total 
number of neutrophils was unknown and the total number of leukocyies was> 
1.5xIO'/I, the report was unclassifiable. Agranulocytosis or neutropenia were 
considered probable, if the nadir of the total number of neutrophils was " 
O.5xIO'/1 or> O.5xIO'/1 but" 1.5xlO'/l respectively, and (unless the patient died) 
the patient recovered after discontinuation of the drug. Bone malTOW examination, 
if perfolTlled, had to show nOlTllal red cell lines and megakaryocyies. The 
hemoglobin had to be;:> 6.5 mmolll and the number of platelets ;:> IOOxlO'/l. If 
the nadir of the total number of neutrophils was" O.5xIO'/1 or > O.5xIO'/1 but" 
1.5xlO'/I, and the patient recovered after discontinuation of the drug, but the 
result of bone man-ow investigation was unknown, as were hemoglobin and the 
number of platelets, agranulocytosis respectively neutropenia were considered 
possible. If the report mentioned "absolute" or "total" agranulocyiosis, this was 
intelpreted as the complete absence of neutrophils. If there was only a bone 
malTOW investigation on autopsy showing no neutrophils and the absolute number 
of neutrophils in the peripheral circulation was unknown, the report was 
nevertheless classified as agranulocytosis probable if the number of 
megakaryocytes and red cell precursors were nOlTllal. If the total number of 
neutrophils was> 1.5xIO'/I, or Hb, Ht or platelets were abnolTllal (see above), or 
bone man-ow investigation was not consistent with agranulocytosis, 
agranuloCyiosis was considered unlikely. 
Secondly, the causal relationship between agranulocytosis or neutropenia and 
the drugs used was classified. The causal relationship between drug and 
agranulocytosis was classified as probable, if the drug had been used during the 
IO-day period prior to the first symptoms of agranulocytosis (challenge), if the 
patient had recovered on discontinuation (ifhe or she survived) (dechallenge), and 
if there was only one possible cause of agranulocytosis. If use of the drug had 
been continued and the patient recovered nevertheless, the drug was not 
considered as causal. FurthelTllore, the patient should not have used cyiostatic 
dmgs, immunosuppressive agents or radiotherapy within six weeks prior to the 
onset of agranulocytosis. Also, there should not be a systemic disease which could 
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have given rise to neutropenia, a neoplasm or granulomatous disease affecting the 
bone marrow, or any other disease presenting as agranulocytosis. If, in addition, 
there had been a positive reaction to rechallenge or a positive lymphocyte 
stimulation test, the causal relationship was classified as certain. If there was more 
than one possible cause of agranulocytosis, the causal relationship of each of these 
was classified as possible. In any other case, the causal relationship was classified 
as unlikely. 
Results 
In the years 1974 to 1994, the DSU received 425 reports of agranulocytosis 
(n~225), neutropenia (n~58), or one of the other aforementioned diagnoses 
associated with drug use (n~142). This group of 425 consisted of 149 men and 
271 women. Of 5 persons the gender was unknown. Of these 425, 112 were 
unclassifiable because age or gender of the patient, or the total number of 
leukocytes at the time of the adverse reaction was unknown. Of the remaining 313 
reports, 100 were classified as agranulocytosis probable, 78 as agranulocytosis 
possible, 8 as neutropenia probable, and 20 as neutropenia possible, whereas in 
107 reports agranulocytosis was considered unlikely, mostly because the clinical 
picture suggested generalised bone marrow depression. In the further analysis, 
only the 206 reports of agranulocytosis or neutropenia will be considered. These 
consisted of 72 men and 134 women, with a median age of 56 (25%-75%: 39-69 
years) and 64 years (25%-75%: 48-73 years) respectively. In 25 patients, the 
course of the adverse reaction was fatal (12%) (Table I). Three patients, however, 
after recovery from agranulocytosis, died due to concomitant illnesses. Four 
patients had not yet fully recovered at the time of reporting. Of ten patients, 
outcome was not known. In 35 reports, the suspected drug had been used before 
but this was not stated in the majority of repOlis. Eleven patients had had the 
same adverse reaction to the suspected drug before, and in these cases the causal 
relationship was classified as "certain". Almost 90% of all drugs had been used 
orally. 
Most conUllon symptoms were fever (106 patients), throat ache, pharyngitis or 
tonsillitis (28 patients), sepsis (27 patients), stomatitis or glossitis (21 patients), 
pneumonia, bronchitis or respiratory insufficiency (18 patients), exanthema or rash 
(17 patients), and skin infection, erysipelas or furunculosis (12 patients). 
Symptoms were not stated in 66 reports. 
Causes of agranulocytosis and neutropenia are listed in Table 2, divided by 
classification (probable and possible), and causal relationship between exposure 
and outcome. There were II reports of probable agranulocytosis and 2 of 
probable neutropenia in which the causal relationship between drug and event was 
classified as "certain!!. The causative drugs were cimetidine, dipyrone, 
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-.l Table 1. General descriptives of the study population (n=206). 9 
'" {l 
Agranulocytosis Agranulocytosis Neutropenia Neutropenia Total ~ 
probable possible probable possible 
'" 
Course died 11 12 25 (12%) 
fully recovered 85 58 6 18 167 (81%) 
unlmown 4 8 I 14 ( 7%) 
Suspected drug used previously yes 17 13 2 3 35 (17%) 
no 3 3 ( 1%) 
unlmown 83 62 6 17 168 (82%) 
Previously same reaction to yes 6 3 1 11 ( 5%) 
suspected drug 
no 4 7 1 13 ( 6%) 
unlmown 90 68 6 18 182 (88%) 
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sulphasalazine, methyldopa, spironolactone, propylthiouracil (n~2), thiamazole, 
co-trimoxazole, gentamicin, and a combination preparation containing 
aminophenazone. The drugs causative of neutropenia were benzylpenicillin and 
indomethacin. The individual drugs most often reported to cause agranulocytosis 
or neutropenia were: dipyrone (n~21), mianserin (n~15), sulphasalazine (n~13), 
co-trimoxazole (n~l1), the group of penicillins (n~9), cimetidine (n~8), the 
thiouracil derivatives (n~8), phenylbutazone (n~8), and penicillamine (n~8). 
Discussion 
This study reviews all reports of agranulocytosis and neutropenia during 20 years 
of reporting in The Netherlands. Several drugs are already well-known causes of 
agranulocytosis, such as the thiouracil derivatives, carbimazole and thiamazole, 
dipyrone, sulphasalazine, and several anti-arrhythmic agents. 
When looking at the numbers of reports of agranulocytosis or neutropenia due 
to a certain drug, a high number could erroneously suggest a high incidence rate. 
Firstly, the numbers of reports of agranulocytosis and neutropenia are accumulated 
over the whole period. As not all drugs were on the market for the full 20 years, 
cases of agranulocytosis to some drugs had to accumulate over much shorter 
periods. Secondly, sales figures of drugs differ enormously. If drug A is used 
more often than drug B, and the percentage of patients developing an adverse 
event is similar to both drugs, one would expect more reports of adverse events 
due to drug A than to drug B. This is generally speaking true, but, thirdly, 
reporting bias may occur. When a drug is newly marketed, for instance, a 
relatively high percentage of adverse events is reported. This may also occur after 
a newly recognized adverse reaction is published in the medical literature. When 
a drug is widely known to cause a certain adverse reaction, however, the number 
of reported events usually declines. Fourthly, when estimating an incidence rate 
on the basis of reporting data and sales figures, this is invariably underestimated 
because of under-reporting and because sales figures are always higher than the 
real amount of drugs used in the population. Therefore, reporting data cannot be 
used to compare drugs with respect to the incidence rate of agranulocytosis, but 
can be used for hypothesis generation. 
Few case series as large as this study have been published. This is inherent to 
the rarity of the adverse reaction. Case reports were published on all drugs listed 
as being frequently reported to the DSU in this article, e.g. mianserin, 
sulphasalazine, phenylbutazone, penicillamine, and dipyrone [3], the group of 
penicillins [4], cimetidine [5], naproxen [6], and the thiouracil derivatives [7,8], 
but also on drugs that were reported as a cause less frequently, such as clozapine 
[9-11], cephalosporins [12], procainamide [13], dapsone [14,15], paracetamol [16], 
and ticlopidine [17]. The DSU published case reports and case series on 
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Table 2. Causes of agranulocytosis/neutropenia (206 patients, more than one cause per patient possible). 
Drug Agranulocytosis! Agranulocytosis! Total (tolal 
neutropenia probable neutropenia possible agranulocytosis) 
A B A B 
Dipyrone 7 5 4 5 21 ( 17) 
Mianscrin 8 2 2 3 15 ( 13) 
Sulphasalazine 6 4 2 13 ( 13) 
Co-trimoxazole 5 4 11 ( 10) 
Anti-arrhythmic agents· 4 4 10 ( 10) 
Penicillins .. 4 3 9 ( 8) 
Thiouracil derivatives ... 4 3 8 ( 8) 
Phenylbutazone 2 2 2 2 8 ( 8) 
Cimetidine 3 4 8 ( 7) 
Penicillamine 2 4 8 ( 7) 
Diclofenac 3 3 7 ( 5) 
Carbamazepine 2 4 7 ( 5) 
ACE-inhibitors# 2 3 6 ( 6) 
Hydrochlorothiazide with 3 3 6 ( 6) 
potassium sparing diuretics 
Indomethacin 4 6 ( 3) 
CepbalosporinsH 2 5 ( 5) 
Oxyphenbutazone 3 5 ( 5) 
Nitrofurantoin 2 5 ( 4) 
Salicylic acid derivatives 4 5 ( 4) 
Clozapine 2 2 5 ( 4) 
Carbimazole 3 5 ( 2) 
Sulphonylurea derivativestml 2 2 4 ( 4) 
Methyldopa 2 4 ( 4) 
Thiamazole 2 2 4 ( 4) 
Nucleosides 4 4 ( 4) 
Aminoglutclhimide 2 4 ( 4) 
Ibuprofen 2 4 ( 4) 
Pentazocine 3 4 ( 3) 
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Drug Agranulocytosis! Agranulocytosis! Total (total 
neutropenia probable neutropenia possible agranulocytosis) 
A B A B 
Levamisole 2 2 4 ( 3) 
Promethazine 2 2 4 ( 3) 
Chloramphenicol 2 3 ( 3) 
Paracetamol and combination 3 3 ( 3) 
preparations 
Perazine 3 ( 3) 
Mebhydrolin 2 3 ( 3) 
Ranitidine 2 3 ( 2) 
Imipramine 2 3 ( 2) 
Other drugs (all mentioned 14 13 10 12 49 ( 42) 
twice or less)l 
Total 81 60 66 69 276 (241) 
A= causal relationship certain or probable 
B= causal relationship possible 
• = procainamide(2), ajrnaline (I). tocainide (I), aprindine (5) and amiodarone (1) 
•• = amoxycillin (I), azlocillin (I), benzylpenicillin (3), phenethicillin (1), cloxacillin (I) and penicillin 
(2) 
.f. = methylthiouracil (I) and propylthiouracil (7) 
# = captopril (5) and enalapril (I) 
U = cephalexin (I), cephazolin (I), cefuroxime (1), cefolaxime (I) and cephradine (I) 
m = gJibenclamide (1) and tolbutamide (3) 
S = phenytoin (2), chlorthalidone (2), sulphamethizole(2), norfloxacin (2), naproxen (2), clomipramine 
(2), trazodone (2), omeprazole (2), alimemazine(2), pirenzepine, ticlopidine, ibopamine, hydralazine, 
nifedipine, spironolactone, nalidixic acid, doxycycline, clilldamycill, gentamicin, fusidic acid, dapsone, 
azapropazone, combination preparations with aminophenazone respectively propyphenazone, sui indac, 
piroxicam, pirprofen, niflumic acid, allopurinol, glafenine, valproate, levodopa with carbidopa, 
chlorpromazine, haloperidol, zuclopenthixoi, zopiclone, cinnarizine, metronidazole, combination 
prepararations with pyrimethamine, and theophylline. 
agranulocytosis attributed to aprindine [18,19], spironolactone [20], ticlopidine 
[21], propylthiouracil [22], pirenzepine [23], trazodone [24], and omeprazole [25], 
and on leukopenia attributed to mianserin [26]. 
Other Adverse Drug Reaction Reporting Systems have also published case 
series on agranulocytosis. The Swedish Adverse Drug Reporting Committee 
published two reports on drug-induced blood dyscrasias [2,27]. Dipyrone and 
antithyroid drugs seemed to cause agranulocytosis most commonly, but also 
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sulphonamides were a frequent cause of all types of drug-induced blood cell 
disorders. The mortality rate among the cases of agranulocytosis was 32%, which 
is higher than the 12% in our study. This high figure, however, may be due to 
reporting bias, as serious cases are more readily reported. A case-history study of 
drug-induced blood disorders was performed at the Group Health Cooperative of 
Puget Sound, consisting of225,OOO members, over the period 1972 through 1981 
[28]. They found 7 hospitalized patients with a granulocytopenia attributable to 
drugs, of which 4 to sulphasalazine. There were 875 patients using sulphasalazine 
during this period. 
Epidemiologic studies have been performed on several drugs. Arneborn and 
Palmblad studied 133 patients admitted because of neutropenia in the Stockholm 
region (1,490,000 inhabitants) over the period 1973-75 [29]. Of these, 45 cases 
were probably drug-induced, giving an annual incidence of 0.001 %. When they 
repeated this study over the years 1976-77 [30], the mortality rate was 27%, 
higher than in the first study (2%). The most frequent causes of agranulocytosis 
were sulphonamides, antithyroid drugs, and phenothiazines. An overview over the 
period 1973-78 related some of the incidence figures to sales figures [31]. The 
highest frequency was found for thenalidine, followed by thyreostatics, 
penicillamine and sulphonamides. Only 35% had been reported to the authorities. 
The m0l1ality rate was 11 %. 
The largest study perfonned was the International Agranulocytosis and Aplastic 
Anemia Study (IAAAS), an international case-control study, in which cases and 
controls were collected from 1980-86. 362 community-acquired patients were 
found, which were compared with a control group. Comparing analgesics, positive 
associations were found for phenylbutazone, oxyphenbutazone, indomethacin and 
dipyrone, but there was considerable variation by region for dipyrone, which the 
authors could not fully explain [32]. The authors also found an excess risk for 
antithyroid drugs [33]. Comparing anti-infective drugs, positive associations were 
found for co-trimoxazole and macrolides [34]. When analysing the data for 
cardiovascular drugs, a positive association was found for propranolol, 
dipyridamole, digoxin, acetyldigoxin, cinepazide, procainamide, and aprindine 
[35]. The IAAAS has been criticized in several publications [36-41] with regards 
to methodology. Ibanez et aJ. continued the data collection that had started 
because of the IAAAS and reported on antiarrhythmic drugs over the period 
1980-1988. A relevant risk was found only for aprindine [42]. 
The pathogenesis of agranulocy1osis is not clear for many drugs. Two types of 
mechanisms playa role: the immune type, which is mediated by drug-induced 
auto-antibodies. The antibodies are directed against mature peripheral granulocytes 
or against their precursors. The other is the toxic type, leading to direct 
destruction of myeloid cells. There are two categories: the drug is either directly 
80 
Drug-associated agranulocytosis: 20 years of reporting in The Netherlands 
toxic or it is toxic due to accumulation of inadequately detoxified or excreted 
metabolic end products [3,43]. Reaction mechanisms affecting the peripheral 
blood cells probably result in agranulocytosis more rapidly than mechanisms 
affecting the bone marrow, since in the latter case there will still be mature cells 
available in the peripheral circulation for a certain period. 
Agranulocytosis induced by pyrazolones, such as aminopyrine or dipyrone are 
examples of the immune mechanism. Amidopyrine-dependent leukagglutinines 
were demonstrated by Moeschlin and Wagner [44]. It was shown that an antigen-
(drug)-antibody complex reacts with receptor sites of the peripheral cells. 
Crossreactivity between aminopyrine and dipyrone was shown to exist. Three 
immunological mechanisms have been postulated [45]. Firstly, formation of a 
complex consisting of the drug and a macromolecule, which leads to induction of 
antibodies that bind the drug. The antibody-drug complex is adsorbed by 
granulocytes (e.g. quinidine). Secondly, binding of the drug to the membrane of 
granulocytes induces antibodies against the drug, which will destroy the 
granulocyte (e.g. penicillins, cephalosporins [12,46]). Thirdly, the drug triggers 
the production of autoantibodies, which react with surface antigens on the target 
cells without the drug itself being involved in the reaction (suggested mechanism 
for levamisole, described after prolonged use of propylthiouracil, procainamide, 
and aprindine [3]). 
Agranulocytosis induced by phenothiazine derivatives, e.g. chlorpromazine, is 
an example of a directly toxic mechanism [43,47,48]. This is an idiosyncratic 
reaction, although there is a relative dose dependency. If the drug is used again 
after recovery in smaller doses, there is usually no relapse, unless enough is given 
for a sufficient time. There are no drug-dependent antibodies. The granulopoietic 
cells themselves are thought to be more susceptible to the effects of the drug in 
individuals who develop agranulocytosis to such drugs, since these patients seem 
to have fewer marrow cells in proliferative cycle [49]. Other drugs thought to 
cause agranulocytosis by a toxic mechanism are clozapine, phenytoin, and beta-
lactam antibiotics [3,50,51]. 
Conclusions 
The drugs most often reported as a cause of agranulocytosis or neutropenia in our 
study were mianserin, sulphasalazine, co-trimoxazole, dipyrone, the group of anti-
arrhythmic agents (notably aprindine), the group of penicillins, cimetidine, the 
thiouracil derivatives, phenylbutazone, and penicillamine. Despite years of 
experience, remarkably few epidemiological data exist on this topic. Further study 
should focus on the incidence rate of drug-induced agranulocytosis or neutropenia 
and compare them with other drugs used for similar indications. 
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7 
The population based case-cohort study in 
pharmacoepidemiology: a nationwide approach 

The population based case-cohort study in pharmacoepidemiology 
1 Introductiou 
Phaonacoepidemiological studies on adverse reactions after marketing of dmgs 
face two specific problems. First, when it concerns serious adverse reactions, 
the incidence will be low, otherwise the dmg would not have been approved 
for marketing, although there may be exceptions to this mle (e.g. antineoplastic 
agents). Clinical trials are not suitable for detecting rare (but sometimes 
serious) adverse effects, since usually only 1000-2000 patients are included in 
these trials. Second, when studying dmgs soon after marketing, the prevalence 
of exposure to the dmg will be low. 
Voluntary reporting systems are useful for signal generation, but these 
systems cannot be used for reliable assessment of incidences or relative risks, 
due to reporting bias and under-reporting of adverse events. Although several 
countries record sales of dmgs, these figures may give an overestimation of the 
use of the dmg, as actual intake is almost invariably lower. Hence, an 
incidence assessment based on reporting data and sales figures will always be 
an underestimation of the actual situation, and will suffer from reporting bias. 
Cohort studies are suitable for studying dmgs with low exposure rates, but 
are not very suitable for studying low exposure and rare adverse reactions 
concurrently. A postrnarketing cohort would be suitable for studying low 
exposure, but in a postmarketing cohort, background incidence figures are 
needed on the outcome of interest, and these are not always available. There 
still would be a problem if the adverse reaction is rare as well, since a sizeable 
cohort would be needed to study the relationship. Case-control studies are 
suitable for studying rare disease but not rare exposure, and are very often 
subject to selection and infoonation bias (Table I). 
Table 1. Quantitative study designs in pharrnacoepidemiology 
Exposure common 
Disease common clinical trial 
Disease rare case-control study 
Exposure rare 
cohort study 
case-cohort study 
In 1975, Kupper, McMichael and Spirtas proposed a new study type: a 
hybrid retrospective [I], later teoned case-referent [2] or case-cohort desigu 
[3]. This design was mainly used in studies on occupational health and in 
cancer prevention trials. As we anticipated that the case-cohort design might 
have advantages in studying rare events to uncommonly used dmgs, we studied 
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whether it would be suitable for phannacoepidemiological studies on a 
nationwide scale. 
2 Theoretical considerations 
In epidemiology, cohort and case-control designs are probably the most 
frequently used study approaches. In phannacoepidemiology, cohort studies in 
the usual sense are infi"equently perfonned. Unlike cohorts based on a common 
and stable factor, e.g. persons with a special genetic trait or blood group, drug 
exposure acts as an 'on-off risk factor. Hence, people who are exposed at one 
point are not exposed at another point in time. Therefore, it is important to 
study drug exposure in a biologically plausible risk period (i.e. compatible with 
the phannacodynamic and phannacokinetic properties of the drug) prior to 
outcome, in cases and non-cases. 
When studying rare diseases, such as anaphylaxis and agranulocytosis, a 
nationwide study may be needed in order to collect enough cases. Usually, the 
risk factors for such rare diseases are studied with a case-control design. When 
the drug of interest is rarely used, however, use of the drug may not show up 
in controls. Of course, this is not a problem if this exposure is also rare or 
absent in cases, but it is if many cases are exposed. Then, an exposure odds 
ratio can only be assessed by atiificial methods, for instance by adding Y. to all 
cells in the 2x2-table. 
In the case-cohort design, a cohort is fanned on the basis of a common 
factor, and data are collected prospectively on development of the outcome of 
interest ("cases"). All cases and a randomly selected sample of the cohort 
(reference cohort) are used in the study. This reference cohort may contain 
some cases. In a phannacoepidemiological case-cohort study, exposure to the 
drug of interest is detennined in cases and compared to that in the reference 
cohort, and expressed as a relative risk (see below). This design is very 
efficient if the detennination of exposure status or other risk factors is 
expensive or time consuming (e.g. the assessment of blood levels of a drug). 
Then specimens can be collected on the whole cohort, and the assessment of 
these can be done afterwards on the cases and the reference cohort only. 
In this thesis, the nationwide cohort is defined as all inhabitants in The 
Netherlands within the study period. This nationwide cohort consists of a 
dynamic population rather than a traditional cohort. Because the Dutch 
population is rather stable, and changes little within the period of, e.g. a year, 
however, this population can be treated as a cohort. Theoretically, all 
inhabitants are followed over time and all symptomatic cases of anaphylaxis 
and agranulocytosis are enrolled. 
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Ideally, the exposure in cases during the risk period would be compared to 
the exposure in all inhabitants during a randomly chosen comparable period. 
Unfortunately, such exposure data are virtually non-existent. Even if available, 
these almost invariably consist of aggregated summary statistics from health 
councils or health maintenance organizations on a usually selective prop0l1ion 
of the total population, or on aggregated sales figures from drug manufacturers. 
Especially when studying a rare disease where drugs are a main causative 
factor, such as anaphylaxis and agranulocytosis, detailed infOlmation on all 
used drugs at an individual level are required. 
In this thesis, it was studied whether a case-cohort design would be a 
feasible and efficient approach when studying these rare and often drug-
induced diseases. Because it comprises serious and life-threatening disorders, 
most symptomatic cases will be admitted to a hospital. Therefore, we enrolled 
all admitted cases in our study. As a reference cohort, we took a sample of all 
pharmacy data in the study period. 
2.1 Data 011 morbidity 
In this thesis, admitted cases of anaphylaxis and agranulocytosis were the 
subject of interest. In The Netherlands, the Dutch Centre for Health Care 
Information maintains a nationwide computerized register of hospital 
diagnoses, in which admission data are filed on a continuing basis from all 
general and university hospitals in The Netherlands. For every admission, data 
include a scrambled identification number (retraceable by the hospital only) 
gender, age, date of birth, hospital identification number, department of 
admission, dates of admission and discharge, one principal diagnosis 
(mandatory) and up to nine additional diagnoses (optional). Diagnoses are 
coded according to the ICD-9-CM. Only principal diagnoses in the registry are 
used. The pIincipal diagnosis is usually the disease which has led to admission. 
The additional diagnoses usually consist of events which took place during 
admission (e.g. thrombosis after an operation). Additional diagnoses are not 
mandatory, and the percentage of additional diagnoses that is recorded differs 
from hospital to hospital, and from physician to physician. These data are 
therefore of only limited use for epidemiological studies. 
For the studies in this thesis, only those patients who were admitted to a 
hospital during the study period because of the disease of interest, were 
included. Diagnoses were validated by reviewing the discharge summary and, 
if necessary, additional information was requested from the physicians involved 
in the treatment of these patients. 
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2.2 Data 01/ exposure 
In the case-cohOli design in this thesis, a reference cohort is used which 
consists of all people in the catchment area of a representative sample of all 
community pha1macies from 6 medium-sized cities and their surroundings in 
different parts of The Netherlands, comprising a population of approximately 
500,000 persons (=3% of the Dutch population). The PHARMO RLS drug 
database of the University of Utrecht contains all drug dispensing data from 
these cities. Data available are total drug dispensing histories of all inhabitants 
of this catclunent area, including a patient identifier (which can only be traced 
to an individual patient name and address via the pharmacy in order to 
guarantee confidentiality), gender and date of birth of the patient, prescriber 
identifier, drug names, dispensing dates, dispensed units, drug strength, and 
units per day used [4]. The end dates are estimated by dividing the number of 
tablets/capsules dispensed by the prescribed daily dose, and adding the 
calculated number of days exposed to the dispensing date. With these data, 
numbers of prescriptions, numbers of exposed individuals, and numbers of 
days exposed per drug are available. Also, data are available on concurrent 
medication on an individual patient level. The exposure in this reference cohort 
is used as an estimation of the exposure in the total cohort, being the total 
population in The Netherlands. 
2.3 Relative risk estimation 
In the current studies, the dynamic population formed by all inhabitants of The 
Netherlands may be considered as a cohort. Cases were all patients who had 
been admitted to a hospital with the diagnosis of interest during the study 
period. All people who were inhabitants of the catchment area of the 
PHARMO RLS drug database formed the reference cohort (Figure 1). 
An estimation was made of the relative risk (RR). This was done by 
dividing the ratio of cases exposed to a particular drug (c,) and non-exposed 
cases (co) by the ratio of cohort members exposed to this drug (b,) and non-
exposed cohort members (bo) as assessed in the PHARMO RLS system [2]. 
This ratio is given as follows: 
RR 
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Miettinen proposed a fmmula for the standard error of the crude case-cohort 
risk ratio using a Chi-square statistic [2]. Greenland [5] proposed a fmmula for 
stratified analysis using a Mantel-Haenszel formula. Prentice [3] developed a 
modification of Cox's proportional hazards model for the rate ratio. NUlminen 
[6] has criticised Miettinen's method in that it would produce too narrow 
confidence intervals, and Greenland's method in that it would fail if just one of 
the strata has a zero cell count, and produced an alternative approach using a 
likelihood procedure. Sato commented on Nmminen's method in that it would 
fail for sparse stratifications because of the use of the unconditional maximum 
likelihood [7,8]. He gave a variance estimate of the Mantel-Haenszel risk ratio 
and a confidence limits method, which is consistent in both large-strata and 
sparse-data. Schouten et al. proposed a pseudo-likelihood relative risk model, 
and a similar approach for multivariate rate-ratio estimation [9]. 
In this study, we used the following fOITUula, which can be used in stratified 
analysis ([7], see also Table 2): 
R = L,bokcJl!(clk+cok+bJ 
S = Lkblkco'/(clk+cok+bJ 
W = L,[( COk +noJclkblk+( Clk +nIJcokbOk+clkllok+cOknlk]/( Clk +COk +bk)' 
R 
RR~rn = 
S 
95%-confidence limits: 
2RS+3.84W±V{3.84W(4RS+3.84W)} 
2S' 
k = 1,2, ... ,K indexes the strata 
Since the number of cases appearing both in the cases (c) as well as in the 
reference cohort (b) is small compared to the total number of persons in the 
reference cohort, we did not remove these from the reference cohort in the 
calculations. 
The two studies on anaphylaxis and agranulocytosis were analysed in a 
different manner. First, in the study on anaphylaxis, a causality assessment was 
pm·fonned on the cases of "anaphylaxis probable" or "anaphylaxis possible", 
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based on the temporal relationship between exposure and anaphylaxis, the 
number of dmgs used prior to anaphylaxis (one or more than one), and, if 
perfonned, on the reaction to a rechallenge with these dmgs. Although a very 
unusual procedure in epidemiology, this strengthened the results of the study, 
since unlikely causes of anaphylaxis were (rightfully) removed prior to the 
relative risk assessment. This procedure was not possible in the study on 
agranulocytosis, since agranulocytosis is not an lion-off" phenomenon, as 
anaphylaxis is, and the relevant period of exposure prior to agranulocytosis is 
much longer than the one prior to anaphylaxis. 
Second, in the study on anaphylaxis, the risk of developing anaphylaxis to 
one dmg or gl'OUp of dmgs was compared to the risk of developing 
anaphylaxis to another drug or group of dmgs. In the study on agranulocytosis, 
the exposure among cases was compared to the exposure in the reference 
cohort. Both methods are valid, and the choice between them depends on the 
hypothesis of interest. In the study on dmg-associated anaphylaxis, due to the 
shOlt relevant period of exposure prior to anaphylaxis, it was possible to 
compare drugs in the relative risk estimate, something which was not the case 
with respect to agranulocytosis. Also, in the study on drug-associated 
anaphylaxis the aim was to compare risks between dmgs (notably glafenine 
versus other analgesics) something which was not essential in the study on 
dmg-associated agranulocytosis. 
Table 2. 
Exposed (E= I) Non·exposed (E~O) Total 
Reference cohort b, bo b 
'"'' 
cj'=b,-n, co"=bo-llo c'=b-n 
non-cases n, n, n 
Cases C, Co C 
In the case-cohort study all cases from the cohort are used. The reference cohort (b) consists 
of a sample of the total cohort, which may contain some cases (c"). The cases c' arc the same 
cases included in the cases (c) and in the reference cohort. 
3 Discussion 
In a situation of rare exposure alld rare outcome, the case-cohort design may 
have advantages. Also, the population based case-cohort design may be 
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relatively efficient, and less prone to selection and information bias. We will 
discuss the advantages and limitations of this design in chapter 10. 
In our studies, we used pharmacy dispensing data for the assessment of 
exposure. In contrast to the original case-cohort design, the study base was a 
dynamic population. Therefore, the cohort is a variable-time or dynamic cohort 
instead of a fixed COhOli because the population in The Netherlands is not 
constant. We think however, that since the population of The Netherlands did 
not change substantially during the study period, we may consider this 
population as a cohort in the classical sense. The exposure, however, is 
variable over time, since patients will start using drugs and may stop again 
within the study period. Another important difference between our study design 
and the traditional case-cohort design is, that our study design is population 
based and nationwide and that the exposure data are not from a random 
sample. Even though, however, dispensing data did not come from a random 
sample of pharmacies, the dispensing data from our sample were representative 
of drug use in The Netherlands, in that the gender and age distribution of drug 
users in the sample were similar to that in the Dutch population. It should be 
emphasised, however, that prescription habits may differ from region to region. 
In order to minimize this problem, we used exposure data from six cities in 
different regions in The Netherlands. When aggregated dispensing data from 
the sample were compared to aggregated sales data from the Dutch Health 
Insurance Fund Council, they were found to be similar. However, for 
individual drugs it is still possible that the regional dispensing data are 
influenced by different prescription behaviour. 
Positive misclassification of exposure may occur when patients do not use 
the dispensed dlllgs, or do not use all dispensed drugs, but stop taking them 
when e.g. only half the amount of dispensed drug is finished because their 
complaints have diminished. Negative misclassification is bound to happen 
with dlllgs that are also available over the counter (OTC-dlllgs), such as 
several NSAIDs, paracetamol, and antacids. Also, data on dlllgs dispensed in 
hospitals or institutions are not available in the PHARMO RLS database. 
Information bias on exposure in studies with data from this database is not a 
problem, since data on dispensed dlllgs are collected before the outcome of 
interest occurs, and we used data from the pharmacy to validate dlllg use in 
cases. Hence, recall bias was excluded. 
The outcomes of interest in this thesis were obtained from all general and 
university hospitals. Positive misclassification of disease could be minimized 
by validation of the diagnoses. Negative misclassification, occurring if patients 
were admitted for the disease, but were coded differently, was minimized by 
including several diagnosis codes in the studies which could have included 
patients admitted for the disease under study. When patients were not admitted 
at all, they were missed, and obviously such negative misclassification is 
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difficult to evaluate. When studying severe adverse reactions, however, the 
percentage of non-admitted patients will be low, although some may have died 
without being admitted. 
Selection bias might occur, when there would be a selective response by 
physicians to our requests for admission data (response bias) or when patients 
with an adverse reaction to one drug were more readily admitted than patients 
with the same adverse reaction to another drug. The first problem had to be 
overcome by getting as high a response as possible. The second problem 
(referral bias) will not be an issue if the design is restdcted to severe adverse 
reactions which always lead to hospital admission, irrespective of previous 
exposure. 
Information bias might occur if data on patients using drug A were better 
recorded and coded than on patients using drug B. We think that the 
completeness of data collection depends more on the disease and its severity 
than on pdor drug use, and therefore this should not have jeopardised the 
validity of the studies. 
Adverse events which happened during hospital admission were not 
included, for two reasons. First, additional diagnoses in the registry of the 
Dutch Centre for Health Care Information were not used in the study for the 
reasons mentioned above. Second, the exposure data fi'om the PHARMO RLS 
database do not cover in-hospital phannacies and even if available, these data 
could not be used, because pharmacies inside hospitals in The Netherlands do 
not have patient-specific, but ward-specific data on exposure. 
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A population based case-cohort study of drug-associated anaphylaxis 
Summary 
In order to determine the risk of anaphylaxis as an adverse reaction to dlUgS, 
a case-cohort study was performed. Cases consisted of all admissions in 1987 
and 1988 to all Dutch hospitals with anaphylaxis as the principal diagnosis, and 
a random sample of admissions with related symptoms. Hospital discharge 
summaries were classified according to probability of anaphylaxis by a blindcd 
Audit Committee. Of admissions classified as probable or possible anaphylaxis, 
the causative agent was assessed. The reference cohOli consisted of all persons 
in the catchment area of a sample of pharmacies in The Netherlands, in the 
period between January I, 1987 and December 31, 1988. 
2 Out of934 admissions, discharge summaries on 81 I admissions were received, 
of which 727 contained enough clinical details. Out of 727, 391 were classified 
as probable or possible anaphylaxis. In 336 of these 39 I, anaphylaxis was 
reason for admission. This group consisted of 158 men and 178 women. Drug-
associated anaphylaxis occulTed in 107 patients. 
3 Dmg-associated anaphylaxis was most frequently caused by penicillins, 
analgesics and non-steroidal antiinflammatory dlUgS (NSAID) with the highest 
point estimate of the risk relative to all other drugs of 10.7, 6.9 and 3.7 
respectively. 
4 In the cases of probable anaphylaxis, the risk of anaphylaxis to glafenine 
relative to all other dlUgS was 167.7 in 1987 (95%-CI: 63.0-446.4) and 128.6 
in 1988 (95%-CI: 50.4-328.5), to amoxycillin 15.2 in 1987 (95%-CI: 5.0-46.0) 
and 4.4 in 1988 (95%-CI: 1.03-18.9) and to diclofenac 6.1 in 1988 (95%-
CI: 1.4-26.1). 
5 The case-cohort design may be useful for postmarketing surveillance. 
Introduction 
In many countries information on adverse reactions to dlUgS is collected by 
volunt81Y reporting of adverse reactions, predominantly by medical practitioners 
and phalmacists. Although voluntary reporting schemes are a useful resource for 
signal generation, the major limitation is that no insight is obtained into the 
incidence or relative risk of adverse reactions, due to non-recognition or under-
reporting of adverse reactions, false attribution of adverse events to drugs, 
reporting bias and the absence of reliable drug consumption data. In the past 25 
years associations between adverse events and drugs have been reported frequently 
in the medical literature and/or to reporting systems. The interpretation of such 
associations and their incidence has posed considerable problems to regulatOlY 
authorities. One example concerns the analgesic glafenine, an anthranilic acid 
derivative which was registered more than 20 years ago ill several European, 
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Asian, South-American and African countries. Since 1972 several cases of 
anaphylaxis have been reported in the literature [1-16] and several hundreds of 
cases have been reported to the Netherlands Centre for Monitoring of Adverse 
Reactions to Drugs. Since a high frequency of reporting does not prove that a 
pa11icular adverse reaction has a high incidence, other methods than voluntary 
reporting had to be used to investigate further the hypothesis that anaphylaxis 
occurs more frequently in response to glafenine than to other analgesics. In a 
previous study with data of the year 1981 [16], it was demonstrated that the risk 
of anaphylaxis to glafenine was higher than to any other "prescription only" drug 
available in The Netherlands. In order to assess whether the situation had changed 
in recent years after the adjustment of the data sheet in 1986 and in order to 
compare the tisk of anaphylaxis to glafenine with the risk of anaphylaxis to 
similar drugs, this study was perfonned. 
Methods 
Design 
In this study a case-cohort design was used [17]. The study base consisted of all 
persons in The Netherlands in 1987 or 1988 (the base cohort). All dispensing data 
over the years 1987 and 1988 from the representative sample ofphannacies were 
considered as a random exposure sample Ii'om the base cohort (the reference 
cohort). This sample was used as the reference source of exposure infonnation. 
All instances of anaphylaxis in the study base as a reason for admission were 
defined as cases, of which the drug exposure was compared to that of the 
reference cohort. 
Morbidity data 
Anaphylaxis is an acute reaction which occurs within 1 h after exposure to a 
substance and which can involve the cardiovascular system (e.g. hypotension), the 
respiratory system (e.g. bronchospasm), the skin (e.g. urticatia) and the gastro-
intestinal system (e.g. dialThoea) [18]. Although immunologically there is a 
difference between anaphylactic and anaphylactoid reactions, it is clinically not 
possible to differentiate between both types of reaction, and in the medical 
literature both mechanisms are refelTed to as anaphylaxis [19]. Therefore, in this 
study both types of reaction were included. 
Data on morbidity were obtained from a nationwide computerized register of 
hospital diagnoses, in which admission data are filed on a continuing basis from 
all general and university hospitals in The Netherlands. Data include gender, date 
ofbi11h, admission and discharge, one ptincipal diagnosis (mandatory) and up to 
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9 additional diagnoses (optional) for every admission. Diagnoses are all coded 
according to the ICD-9-CM. We included all admissions in the study conceming 
patients who had been discharged in 1987 or 1988 with one of the following 
principal diagnoses: 995.0 (anaphylactic shock, including allergic shock, 
anaphylactic reaction and anaphylaxis: 253 admissions), 995.4 (shock due to 
anaesthesia: 0 admissions), 999.4 (anaphylactic shock due to serum: 3 admissions) 
and 989.5 (venom; insect stingsfbites: 202 admissions). Code 989.5 was included 
because cases of anaphylaxis to insects could have been classified as an insect 
sting or bite. Because some cases of anaphylaxis could have been classified under 
another diagnosis code (e.g. urticaria or allergy), a random sample was obtained 
of the following principal diagnoses: 693.0 (dermatitis due to drugs and 
medicaments: 120 admissions), 695.0 (toxic erythema: 36 admissions), 708.0 
(allergic ut1icaria: 60 admissions), 995.1 (angioneurotic oedema: 80 admissions), 
995.2 (unspecified adverse effect of drug, medicament and biological: 120 
admissions) and 995.3 (allergy, unspecified: 60 admissions). 
Exposure data 
Data on dispensed drugs were obtained from a representative sample of 28 
pharmacies from different parts of The Netherlands with a catchment area 
comprising a population of approximately 100,000 persons (562,855 prescriptions) 
in 1987 and 150,000 persons (832,856 prescriptions) in 1988 (~1% of the Dutch 
population), as kept by the PHARMO exposure database [20]. This population 
fOlmed the reference cohort. The vital statistics conceming age (stratified in 15-
year age groups) and gender in this reference cohort were the same as in the 
population in The Netherlands (Chi square ~ 8.1, 11 degrees of freedom; p~O. 7). 
Numbers of prescriptions, exposed individuals and days at risk were used as the 
denominator in the relative risk assessments. Days at risk were calculated by 
dividing the total number of dispensed tablets/capsules per patient by the 
prescribed daily intake of tablets/capsules. 
Procedures 
The physicians involved in the treatment of the patients with anaphylaxis were 
asked to provide clinical details at admission by sending an anonymised copy of 
the discharge summaIY of the patients in the study. If the copy of the di'scharge 
summary did not contain enough details, further information was requested. 
An Audit Committee of three experienced consultants in intemal medicine 
assessed the clinical details, blinded with regards to the identity of the patient, 
physician and hospital, and all possible causes of anaphylaxis. Description of 
symptoms and signs and of the course of the illness during admission were left 
unchanged. Every admission was analysed according to a predefined algorithm by 
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which each admission was classified as either "anaphylaxis probable", 
"anaphylaxis possible", "anaphylaxis unlikely" or "admission unclassifiablell • 
Discharge summaries had to contain details on gender, date of birth and admission 
of the patient and symptoms of the reaction. If not available, the admission was 
judged as "admission unclassifiable". An admission was classified as "anaphylaxis 
probable" if the patient had suffered from symptoms characteristic of anaphylaxis, 
i.e. symptoms out of two or more of the following four systems (with the 
exception of a combination of system I and 4) and if the reaction had occurred 
within one hour after exposure to the causative agent (or had been specified as 
IIshortly" or "immediately" after exposure): 
I. Cardiovascular system: collapse, loss of consciousness, hypotension 
(systolic blood pressure';; 100 mm Hg and symptoms characteristic of 
hypotension or, in case of hypertension, a blood pressure that gave 
symptoms characteristic of hypotension). 
2. RespiratOlY system: rhinitis, swelling of the uvula or phatynx, laryngeal 
edema (stridor), bronchospasm (dyspnoea, wheezing, asthma). 
3. Skin and conjunctiva: plUritus, erythema, urticaria, angioedema, 
conjunctivitis. 
4. Gastro-intestinal system: nausea, vomiting, diarrhoea, fecal urge, abdominal 
pain or spasm. 
If the patient had suffered from symptoms compatible with -but not characteristic 
of- anaphylaxis, i.e. symptoms out of only one of the systems 1, 2 or 3 or the 
combination of system I and 4, an admission was classified as "anaphylaxis 
possible" if the reaction occurred within I h or if the time interval between 
exposure and reaction was unknown. If the symptoms were characteristic of 
anaphylaxis, but the reaction had occurred later than an hour after exposure or this 
time period was unknown the admission was also classified as "anaphylaxis 
possible". In any other case the classification was "anaphylaxis unlikely". Each 
member of the Audit Committee classified first every individual admission 
separately. Subsequently, final classification was decided on by consensus or by 
majority of votes. If no agreement was attained, the admission was classified as 
"admission unclassifiable". An anaphylactic reaction was classified as severe if it 
was generalized and potentially life-threatening. This was the case if the patient 
was suffering from cardiovascular or respiratory symptoms or if there was 
in-eversible damage (e.g. myocardial infarction). 
In all cases of "anaphylaxis probable" or "anaphylaxis possible" in which the 
reaction had been the reason for admission, the causal relationship between 
exposure and reaction was assessed according to previously defined and accepted 
criteria [21]. Basically, the exposure-anaphylaxis-association was classified as 
"causal relationship probable" if the patient had been exposed to olle suspected 
cause shortly before developing anaphylaxis, and as "causal relationship certain" 
if, in addition, there had been a positive reaction to rechallenge. The exposure-
104 
A population based case-cohort study oj drug-associated anaphylaxis 
anaphylaxis-association was classified as "causal relationship possible" if the 
patient had been exposed to more than one potential cause shortly before 
anaphylaxis. The exposure-anaphylaxis-association was classified as "causal 
relationship unlikely" if the temporal relationship was incompatible. Also, cases 
in which the exposure did not precede the reaction (challenge), in which 
discontinuation was not followed by recovery ofa reversible event (dechallenge), 
or in which continuation or readministration (rechallenge) did not cause a relapse, 
were classified as "causal relationship unlikely". 
Dala analysis 
An estimation was made of the relative risk (RR) of responding to drug X with 
anaphylaxis compared to drug Y, classified according to the Anatomical 
Therapeutic Chemical (ATC) system. Every separate admission classified as 
"anaphylaxis probable" was considered as a case of anaphylaxis. The relative risk 
was assessed as follows: 
number of cases of anaphylaxis due to drug X 
number of cases of anaphylaxis due to drug Y 
RR=-----------------------------------------
number of prescriptions for drug X in reference cohort 
number of prescriptions for drug Y in reference cohort 
Point-estimates were calculated with their 95% confidence intervals [22]. 
Similarly, relative risk estimations were performed with, in the denominator, the 
number of exposed individuals and the total number of days at risk per drug. 
Also, relative risk estimations were performed with, in the denominators of the 
upper and lower quotient, the number of all cases of anaphylaxis to all drugs 
except drug X, respectively the total number of prescriptions for all drugs except 
drug X. In order to see whether this would influence the relative risk estimation, 
re-analyses were performed with admissions classified as "anaphylaxis possible". 
The inter-observer agreement in the Audit Committee was analysed by a 
weighted kappa test [23]. 
Results 
Physicians responded to requests for information in 811 out of 934 admissions 
(87%). In 84 admissions the data were insufficient, either due to lack of clinical 
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details (n~9), or because the consultant refused or failed to co-operate (n~44), or 
because the patient's file could not be found (n~29) or because the reporting 
physician did not consider the admission as relevant to this study (n~2). 
The Audit Committee classified the remaining 727 discharge summaries as 
"anaphylaxis probable" (n~153), "anaphylaxis possible" (n~238), "anaphylaxis 
unlikely" (n~309) and as "admission unclassifiable" (n~27). A total of 632 
admissions consisted of reactions which occurred outside the hospital and which 
were the direct reason for admission (community acquired). The remaining 95 
consisted either of reactions in the outpatient clinic (n~58) or inside the clinic 
during admission (n~24) or of reactions on something which was bought or 
encountered outside The Netherlands and therefore could not be related to drug 
dispensing data inside The Netherlands (n~3). The place of reaction was not 
mentioned in the remaining discharge summaries (n~lO) and therefore this could 
not be used to distinguish those cases in which the reaction was the direct reason 
for admission from the others. Of the 632 reactions which were reason for 
admission, 119 were classified as "anaphylaxis probable", 217 as "anaphylaxis 
possible", 278 as "anaphylaxis unlikely" and 18 as "admission unclassifiable" 
(Figure 1). 
Of the admissions coded as diagnoses 995.0 and 999.4, 25 (12%) were 
classified as "anaphylaxis unlikely" by the Audit Committee. Some of these 
patients had been admitted with a reaction that was not anaphylaxis but, for 
example, a Herxheimer reaction, a toxic shock, an intoxication to a drug, collapse 
after use of nitroglycerin or convulsions. Two were diagnosed as hyperventilation. 
As a consequence, the definite false-positive misclassification was 12% in these 
groups. Out of categories 995.0 and 999.4, 174 admissions were classified as 
"anaphylaxis probable" or "anaphylaxis possible" (85% of the analysed admissions 
of these diagnosis categories). Of the cases classified as "anaphylaxis probable", 
69 came out of the 522 admissions from the other diagnosis categories, mainly 
Ii-om category 989.5 (venom; insect stingslbites). This makes the definite false-
negative misclassification 13% in these categories. If category 989.5 was 
excluded, the false-negative misclassification was only 4% (I5 cases out of 356 
admissions of which data ,vere received and which were classified by the Audit 
Committee). 
Weighted kappa was reasonably high and remained that way throughout the 
study (0.55-0.77), which means that the agreement on classification was 
satisfactory and that the members of the Audit Committee were consistent in their 
classification. 
In the total study there were four deaths: one patient died of a toxic shock, one 
during a catheter procedure in order to remove stones from the choledochal duct 
and two patients died of anaphylaxis to intravenously administered contrast media. 
There were also 21 cases of non-fatal anaphylaxis due to contrast-media. 
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FigUl'C 1. Overview of study results. 
I Total number of admissions in study: 9341 P hase l:Data collection 
I Response: 811 (~87%) I 
I Classified by Audit Committee: 727 I 
p hase 2:Classification of disease 
I II Total 
, Anaphylaxis 119 34 153 
probable' 
, Anaphylaxis 217 21 238 
possible' 
, Anaphylaxis 278 31 309 
unlikely' 
'Admission 18 9 27 
unclassifiable' 
Total 632 95 727 
P hase 3: Causality assessment 
(n~336) 'Causal relationship certain' or 
'causal relationship probable' (n=252): 
Insects 120 (48%) 
Drugs 107 (42%) 
Food 21 (8%) 
Miscellaneous 4(2%) 
= Reason for admission. 
II = Occurred in outpatient clinic, clinic, outside The Netherlands Of place of reaction 
unknown. 
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Only the reactions which occurred outside the hospital and led to admission and 
which were classified as "anaphylaxis probable" or "anaphylaxis possible" are 
used in the further analysis. This group consisted of 336 cases, 158 men and 178 
women with a median age of 42.5 years (mean 41.0, range 2-84 years, SD 20.4) 
and 46.5 years (mean 44.9, range 1-90 years, SD 21.5) respectively. Symptoms 
recorded in the discharge summaries are summarized in Table 1. 
Table 1. Symptoms· of 336 patients admitted because of anaphylaxis ("Anaphylaxis probable" 
(n~119) and "Anaphylaxis possible" (n~217)). 
Symptoms "Anaphylaxis "Anaphylaxis Total 
probable" possiblell 
Erythema 76 (64%) 115 (53%) 191 (57%) 
Angioedema 65 (55%) 107 (49%) 172 (51%) 
Hypotension 66 (55%) 56 (26%) 122 (36%) 
Bronchospasm 61 (51%) 57 (26%) 118 (35%) 
Pruritus 40 (34%) 77 (35%) I17 (35%) 
Urticaria 34 (29%) 71 (33%) 105 (31%) 
Collapse 42 (35%) 45 (21%) 87 (26%) 
Nausea/vomiting 23 (19%) 43 (20%) 66 (20%) 
Tachycardia 29 (24%) 34 (16%) 63 (19%) 
Loss of consciousness 24 (20%) 22 (10%) 46 (14%) 
Diarrhoea 6 (5%) 17 ( 8%) 23 (7%) 
Upper airways .. 12 (10%) 9 (4%) 21 ( 6%) 
Conjunctivitis 12 (10%) 9 (4%) 21 ( 6%) 
Laryngeal edema 8 (7%) II ( 5%) 19 ( 6%) 
Abdominal pain 7 (6%) 12 ( 6%) 19 ( 6%) 
Bradycardia II ( 9%) 4 (2%) 15 ( 4%) 
There were also 13 patients in the group flanaphylaxis probablelt and 9 patients in the group 
"anaphylaxis possible lt with symptoms of cardiac and/or cerebral ischemia. one of them 
needing mechanical ventilation . 
.. Rhinitis, oedema of the uvula or pharynx. 
In 252 of the 336 admitted cases classified as "anaphylaxis probable" or 
"anaphylaxis possible" the suspected agent had been classified as "causal 
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relationship certain" or "causal relationship probable". In those 252, an insect was 
the cause in 120 cases, a drug in 107 cases, food in 21 cases and in 4 cases it was 
something else such as a cleaning agent, a burst echinococcus cyst, or exercise-
induced anaphylaxis (Table 2). 
Table 2. Causes of anaphylaxis leading to admission with a "causal relationship certain" or a 
1!causal relationship probableu . 
"Anaphylaxis IIAnaphylaxis Total 
probable" possible" 
Insects 63 57 120 
Food 10 II 21 
Drugs 
glafenine 12 8 20 
amoxyci1lin 6 6 12 
diclofenac 2 6 8 
analgesics with paracetamoi (including 5 2 7 
propyphenazone) 
enalapril 4 4 
co-trimoxazole 4 4 
dipyrone 2 3 
nitrofurantoin 2 3 
carbaspirin calcium 2 3 
desensitization agents 2 3 
amoxycillin + clavulanic acid 3 3 
phenethicillin potassium 2 
nifurtoinol 2 2 
trimethoprim 2 2 
naproxen 2 2 
aspirin 2 2 
miscellaneous drugs (all mentioned once) 10 17 27 
Other causes 3 4 
Total 114 138 252 
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Table 3. Relative risks of glafenine, diclofenac, amoxycillins, analgesics, penicillins and NSAID versus all other drugs in 1987. Q 
.g 
RR (CI 95%) ~ 
Drug class Prescriptions Anaphylaxis Anaphylaxis probable(A) Anaphylaxis possible (B) Anaphylaxis probable or 00 
(ATC-code in brackets) hospitalisations Anaphylaxis possible (C) 
(n = 562,855) A B C 
Glafenine 1667 6 6 12 167.72 (63.02 - 446.36) 84.01 (34.39 - 205.26) 111.62 (58.18 - 214.15) 
(N02BG03) 
Amoxycillins 10410 4 5 9 15.16 (4.99 - 46.04) 10.63 (4.07 - 27.76) 12.26 (5.94 - 25.30) 
(JOICA04, JOICA54) 
Analgesics with paracetamol 20062 3 4 5.41 (1.57 - 18.69) 0.93 (0.13 - 6.86) 2.46 (0.89 - 6.86) 
(N02BEOI, N02BE51, 
N02BE71) 
Diclofenac 7471 0 2.57 (0.35 - 18.85) 1.58 (0.22 - 11.48) 
(MOIAB05) 
Penicillins 14624 4 5 9 10.71 (3.53 - 32.53) 7.51 (2.88 - 19.61) 8.66 (4.20 - 17.88) 
(JOIC, JOIR, JOIJ) 
NSAID 21223 2 2 4 3.19 (0.73 - 13.87) 1.83 (0.44 - 7.67) 2.32 (0.84 - 6.47) 
(MOlAA, MOIAB, MOlAE) 
Analgesics 27403 4 3 7 5.58 (1.84 - 16.96) 2.18 (0.66 - 7.17) 3.34 (1.50 - 7.45) 
(N02BA, N02BB, N02BE) 
CI 95% = Confidence Interval 95% calculated according to Miettinen (22}. 
Table 4. Relative risks of glafenine. diclofenac. amoxycillins, analgesics, penicillins and NSAID versus all other drugs in 1988. 
RR (CI 95%) 
Drug class Prescriptions Anaphy1axis Anaphylaxis probable(A) Anaphylaxis possible (B) Anaphylaxis probable or ~ 
(ATC-code in brackets) hospitalisations Anaphylaxis possible (C) 
'" (n~832,856) A B C ~~ Glafenine 2415 6 2 8 128.63 (50.38 - 328.45) 19.63 (4.72 - 81.59) 53.77 (25.54 - 113.17) 6' (N02BG03) 
" 
4.42 (1.03 - 18.92) 2.37 (0.74 - 7.57) '>" Amoxycillins 18412 2 3 1.23 (0.17 - 8.96) 
" '"' (JOICA04, J01CA54) 
'" "-
Analgesics with paracetamol 30379 2 3 2.64 (0.62 - 11.30) 0.73 (0.10 - 5.35) 1.42 (0.44 - 4.52) <") t; (N02BE01, N02BE51, 
'" 
, 
N02BE71) 8 
""" Diclofenac 13423 2 5 7 6.10 (1.43 - 26.11) 9.54 (3.72 - 24.47) 8.21 (3.73 - 18.08) ~ (M01AB05) 
"-
Penicillins 25403 3 8 11 5.02 (1.49 - 16.96) 8.77 (4.01 - 19.17) 7.28 (3.78 - 14.02) " ~(J01C, JOm, JOU) 
.Q., 
NSAID 34322 3 6 9 3.67 (1.09 - 12.41) 4.50 (1.88 - 10.79) 4.19 (2.06 - 8.51) ~ (M01AA, M01AB, M01AE) ~ 
Analgesics 42683 6 4 10 6.94 (2.72 - 17.74) 2.24 (0.79 - 6.33) 3.78 (1.91 - 7.46) 
" '"' (N02BA, N02BB, N02BE) 
'"' c
<") 
CI 95% "" Confidence Interval 95% calculated according to Miettinen [22]. ,,' 2: 
§ 
.g 
~ 
fS 
0;;' 
-
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Of the abovementioned 107 drug-associated cases, glafenine was 20 times the 
causative agent (19%), amoxycillin 12 times (11 %), diclofenac 8 times (7%) and 
combination preparations with paracetamol 7 times (7%) (of which in 6 cases 
(6%) propyphenazone was included in the preparation) (Table 2). There were no 
patients admitted more than once because of drug-associated anaphylaxis during 
the study-period. 
Of the 107 cases 8 (7%) had been rep0l1ed to the Netherlands Centre for 
Monitodng of Adverse Reactions to Drugs as cases of suspected drug-associated 
anaphylaxis, as was determined by comparing biI1h date, gender and date of 
admission in both files. 
Tables 3 and 4 show the absolute number of anaphylactic reactions per drug or 
dmg group and the risks of anaphylaxis, relative to the total number of 
prescriptions in 1987 and 1988 separately. Although there is vadation per year 
and per probability class A-C, the point estimates of the relative risks of 
anaphylaxis to glafenine, amoxycillins, diclofenac, penicillins and analgesics are 
invariably distinctly greater than one in the group "anaphylaxis probable". The 
lower relative risks in the groups including cases classified as "anaphylaxis 
possible" (B and C) may be attributed to non-differential misclassification of 
disease [24). The latter resulted from the fact that the group "anaphylaxis 
possible" included cases in which anaphylaxis could not be excluded but was not 
very likely either (e.g. ninth-day rash to amoxicillin). Therefore, we concentrated 
our analysis on the group "anaphylaxis probable". The drug with the highest 
relative risks was glafenine. In order to assess the risk relative to other well-
known causes of anaphylaxis, glafenine was compared with drugs that had been 
the causative agent of anaphylaxis more than four times in this study. Glafenine 
was also compared with the group of antiinflammatory and antirheumatic drugs 
(NSAID), with salicylic acid and its derivatives and, since it is a non-narcotic 
analgesic, with the total group of non-narcotic analgesics except, of course, for 
glafenine (Table 5). The relative risk estimation was made on the basis of 
prescdptions and numbers of patients in the two-year pedod 1987-1988. Use of 
glafenine had the highest risk of anaphylaxis in all analyses. When comparing 
glafenine with combination preparations containing paracetamol the point 
estimator of the relative risk was (prescriptions and exposed patients respectively) 
24.7 - 24.7, with diclofenac 30.7 - 29.6, with NSAID 32.7 - 26.0, with salicylic 
acid and dedvatives 27.7 - 27.0 and with analgesics 20.6 - 18.6. Analysis on the 
basis of days at risk gave similar figures as analysis on the basis of prescdptions 
and exposed patients. We also made a comparison with penicillins, since 
penicillins have a well-known and well evaluated risk of anaphylaxis. This gave 
rise to a relative risk of 16.8 (8.5 < RR < 33.3) (prescriptions) and 20.0 (lOA < 
RR < 38.6) (exposed patients). 
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Table 5. Relative risk in the group "anaphylaxis probable" (glafenine versus control drug, 
1987 and 1988), estimated on the number of prescriptions and exposed patients. 
Relative Risk (+ 95%-confidence limits) 
Glafenine/Control Dmg Prescriptions 
GlafenineiAnalgesics with paracetamol 24.7 (12.S - 47.S) 
GlafeninelDiclofenac 30.7 (Il.S - 79.9) 
GlafeninelNSAlD 32.7 (16.9 - 63.0) 
GlafenineiSalicylic acid and 27.7 (10.4 - 73.9) 
derivatives, incl. combinations 
Glafenine/Analgesics 20.6 (1l.5 - 37.1) 
Discussion 
Exposed patients 
24.7 (12.S - 47.7) 
29.6 (1l.3 - 77.7) 
26.0 (13.0 - 52.0) 
27.0 (10.1 - 72.3) 
IS.6 (10.2 - 33.9) 
This study shows that drugs and insect stings were by far the most impOliant 
cause of admission because of anaphylaxis in The Netherlands in 1987 and 1988. 
Glafenine, amoxycillins and diclofenac were the three most important causes of 
admission because of drug-associated anaphylaxis. Although there were also 23 
cases of contrast-media-induced anaphylaxis, these occurred during admission or 
in the outpatient clinic, and hence these could not be related to the drug 
dispensing data from community pharmacies. For this study we considered 
several types of epidemiological design. Because of the low incidence of 
anaphylaxis, we did not consider a cohort study as a useful approach. Case-control 
studies are very suitable for studying rare diseases and are often used when a 
relationship between the adverse event and a drug is uncertain. In case of 
anaphylaxis, however, the temporal relationship and clinical pattelll usually leave 
little doubt concellling the causal relationship. We had several reasons for not 
using a case-control design. Firstly, recall bias would have been introduced into 
the study. As anaphylaxis is a rapidly developing and impressive type of reaction 
that patients are not likely to forget, it would not have been easy to find controls 
subject to the same recall of exposure as cases. Secondly, as dlllgS are a well-
known cause of anaphylaxis, physicians might inquire more insistently about drug 
use in the index than in the control group. Thirdly, although anaphylaxis is 
considered to be a rare disease, the low population exposure prevalence of some 
drugs (e.g. glafenine) could consequently have meant that none of the controls 
would have been exposed to those drugs. Therefore, we used a case-cohort design, 
in which the cases were all patients admitted because of anaphylaxis in The 
Netherlands in 1987 and 1988 and the control cohort was a reference cohort of 
the Dutch population. 
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Theoretically, our analysis could have been adversely influenced by three 
issues. Firstly, diagnostic suspicion bias or referral bias could have played a role. 
Because of the characteristic pattern and temporal relationship however, and 
irrespective of the causative agent, anaphylaxis is mostly recognized. It is highly 
unlikely that general practitioners would recognize anaphylaxis to one drug (e.g. 
diclofenac) more easily than that to another (e.g. glafenine). Similarly, general 
practitioners decide on admission of their patients to the hospital on the basis of 
severity instead of cause. Hence it is unlikely that they would tend to admit more 
patients with anaphylaxis to one particular type of exposure. This brings us to the 
second issue: in this study cases of anaphylaxis that were not admitted to a 
hospital were not included. This could mean that, if anaphylaxis to one drug was 
more severe than anaphylaxis to another, patients with anaphylaxis to such a drug 
would have been admitted relatively more often than patients with anaphylaxis to 
other drugs. However, there are no reasons to believe that anaphylaxis to orally 
administered amoxycillin, diclofenac or glafenine has a worse prognosis than 
anaphylaxis to other orally administered drugs. Hence, this will mean that the 
proportion of community acquired cases of anaphylaxis which leads to admission 
is more or less the same for these drugs. Thirdly, the reference cohort was not a 
random sample from the total study base. Random samples are, however, not a 
goal in itself but used to ensure that the exposure data are representative of the 
total study base. It is logistically impossible to take a random sample from the 
total study base of all inhabitants in The Netherlands. Instead of this we used a 
representative sample of community pharmacies, located in different parts of the 
country. Therefore, differences in prescribing by medical practitioners in different 
parts of the country played no role. Thus, we are not aware of any reasons to 
suggest that the exposure in the reference cohort differs substantially from the 
exposure in the total study base, especially not as the vital statistics concerning 
age and gender of the reference cohort were the same as that of the population in 
The Netherlands. 
This study was restricted to principal diagnoses and thus no additional 
diagnoses have been analysed. The reason is that reporting of additional diagnoses 
is voluntary. This means that the reporting of additional diagnoses varies per 
hospital, and it is unknown what percentage of the additional diagnoses is 
repOJied. For this reason, in this study the cases of anaphylaxis that occurred 
inside the hospital were not included. Moreover, the dispensing data from hospital 
pharmacies are rarely registered on an individual patient level. 
The most valid relative risk estimations were made with the group "anaphylaxis 
probable". This is obvious, in view of the fact that the group "anaphylaxis 
possible" comprised many non-anaphylactic hypersensitivity reactions. Hence, this 
introduced a misclassification bias towards a relative risk of one in the combined 
group of "anaphylaxis possible" and "anaphylaxis probable" [24] (Tables 3 and 
4). 
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Of the group "anaphylaxis probable" 117 out of 119 cases were considered 
severe on the grounds of involvement of the cardiovascular andlor the respiratory 
system. For the same reason, of the group "anaphylaxis possible" 125 out of 217 
were considered severe. Re-analysis with severe cases did not substantially alter 
the relative risk comparisons between the drugs. Moreover, since every case in 
this group ,has led to a hospital admission, every case should be considered as 
severe. ~ .-
The current study confirms the results of an earlier one [16] of a different 
design. In the current study, besides all cases classified as anaphylaxis, a random 
sample of cases with other diagnoses was investigated, in order to assess false-
negative misclassification. Secondly, all cases were analysed by a blinded Audit 
Committee in order to prevent classification bias due to knowledge of the cause. 
Thirdly, relative risk estimations were made with drug dispensing data instead of 
reimbursement figures from health insurance funds. The fonner more accurately 
reflect the consumption of drugs as dispensing data are available on an individual 
level and as all socio-economic groups are included. 
In the current study more cases of anaphylaxis to insect stings were recorded, 
largely due to the fact that diagnosis code 989.5 (venom; insect stingsfbites) was 
included. The highest risk of community acquired drug-associated anaphylaxis was 
recorded for the individual agents glafenine, amoxycillin and diclofenac. The risk 
of anaphylaxis to glafenine relative to penicillins was consistent with the results 
of the previous study. In the previous study, however, no cases of anaphylaxis to 
amoxycillin and diclofenac were recorded. 
In the absence of reliable outpatient diagnoses this study yields no incidence 
figures. As the risk of anaphylaxis to penicillins has been estimated at 
approximately 1: 1 0,000 prescriptions [25-27], and the lower 95% confidence limit 
of the relative risk versus this group varies from 5 to lOin the series of analyses, 
the incidence of anaphylaxis to glafenine may be estimated at 1: 1,000 to 1:2,000 
prescriptions and hence of diclofenac at approximately 1: 10,000 to 1 :20,000. 
Partly based on the current study, the Committee on Proprietary Medicinal 
Products (CPMP) of the European Community decided to issue a negative opinion 
on glafenine, which was suppOlied by 10 of the 12 member states [28]. This 
advise has been followed by the withdrawal of glafenine in several countries (e.g. 
The Netherlands, Spain). 
We conclude that the case-cohort design -as employed in our study- may be 
useful for poshnarketing surveillance. Unlike a traditional case-control study 
which requires the enrolment and exposure assessment of controls for every study, 
the sample cohort of a case-cohort study may be used as a reference for several 
post-marketing surveillance studies. Moreover, a case-cohort design is suitable for 
studying rare events to rare exposure. This could make the case-cohort design 
useful for studying new adverse events in the first two years of marketing of 
drugs which still have a low exposure prevalence. 
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A populalion based case-cohort study of drug-associated agranulocytosis 
Summary 
In order to determine the risk of drug-associated agranulocytosis as a reason 
for admission to Dutch hospitals, a population based case-cohort study was 
perfonned. Hospital discharge data came from the Dutch Centre for Health 
Care Information. The reference cohort consisted of all persons in the 
catchment area of the PHARMO system in The Netherlands, comprising a 
population of approximately 220,000-484,000 persons in the period 1987-1990. 
All admissions in the years 1987-1990 to all general and university hospitals 
in The Netherlands with agranulocytosis or related diagnoses were included in 
the study (n~923). A copy was requested of the hospital discharge summaries, 
and the laboratOlY and bone marrow results. These were classified according to 
probability of agranulocytosis without knowledge of exposure status. After 
ascertainment of diagnoses, the potential causes of agranulocytosis were 
assessed in all cases which had been classified as probable or possible 
agranulocytosis. 
Discharge summaries were received of 753 admissions, of which 678 
contained enough information for analysis. Out of 678, 108 were classified as 
agranulocytosis probable or as agranulocytosis possible. In 75 of these 108 
cases, agranulocytosis had been the reason for admission. Of these 75 cases, 15 
patients had used thiamazole within 10 days prior to developing 
agranulocytosis, 2 carbimazole, 9 sulphasalazine, 8 co-trimoxazole, 4 
clomipramine, and 2 dipyrone with analgesics, yielding adjusted relative risks 
of agranulocytosis to thyreostatic drugs of 114.8 (95%-CI: 60.5 - 218.6), to 
sulphasalazine of 74.6 (95%-CI: 36.3 - 167.8), to cotrimoxazole of 25.1 (95%-
CI: 1l.2 - 55.0), to clomipramine of 20.0 (95%-CI: 6.1 - 57.6), and to 
dipyrone with analgesics of 26.4 (95%-CI: 4.4 - 111.1). 
In conclusion, the highest relative risks were found for thyreostatic agents, 
co-trimoxazole, sulphasalazine, clomipramine, and dipyrone combined with 
analgesics. 
Introduction 
Agranulocytosis is a life-threatening disorder, which frequently occurs as an 
adverse reaction to drugs [1]. Some drugs are well known causes of 
agranulocytosis, but there are several drugs of which this is less certain. In the 
medical literature, case reports continue to appear about agranulocytosis as an 
adverse reaction to drugs, but the risk of these drugs, expressed as a relative 
risk or incidence is difficult to estimate. In the years 1980-1986 the 
lntemational Agranulocytosis and Aplastic Anemia Study (IAAAS) was 
performed, a population based case-control study involving several study 
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centres across Europe and in Israel, and encompassing a potential population 
base of approximately 23 million people [2-18]. We perfOlmed a study in The 
Netherlands for the following reasons: first, in the IAAAS large differences in 
relative risks between regions in Europe were found, and no epidemiological 
study has ever included .11/ admitted cases of agranulocytosis from a whole 
country. Moreover, the IAAAS was criticized for potential biases inherent in 
its design [15,17]. Second, the IAAAS encompassed the years 1980 to 1986. 
Meanwhile, other drugs have been developed and marketed. We therefore 
performed a study to assess the relative and attributable risks of drug-
associated agranulocytosis in The Netherlands, with a population based case-
cohort design. 
Material and methods 
Sellillg 
Data on morbidity were obtained from the Dutch Centre for Health Care 
Information, which holds a standardized computerized register of hospital 
diagnoses. Admission data are filed on a continuous basis from all general and 
university hospitals in The Netherlands. Whenever a patient is discharged from 
a hospital, data on gender, date of birth, date of admission and date of 
discharge, one principal diagnosis (mandatory) and up to 9 additional diagnoses 
(optional) are anonymously recorded. All diagnoses are coded according to the 
International Classification of Diseases (ICD-9-CM). At the time of initiation 
of this study, the most recent years on file available were 1987-1990. In this 
study, we analysed all records containing potential cases of agranulocytosis, i.e. 
admissions with the ICD-9-CM codes 288.0 (agranulocytosis), 288.1 
(functional disorders of neutrophil polymorphonuclears), 288.2 (genetic 
anomalies of leukocytes), and 288.9 (unspecified diseases of white blood cells) 
as principal diagnoses. 
Data on dispensed drugs were obtained from the PHARMO Record Linkage 
System (PHARMO RLS) with an increasing catchment area of approximately 
220,000 persons in 1987, 331,000 persons in 1988, 419,000 persons in 1989, 
and 484,000 persons in 1990. The vital statistics concerning age (overall and 
stratified) and gender were similar to those of the total Dutch population. 
St/ldy desigll 
In this study a population based case-cohort design was used, in which drug 
use in cases was compared to drug use in a reference cohort [19]. In the case-
cohort design, the reference cohort may contain one or more cases. Cases were 
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patients admitted to a hospital with a validated diagnosis of agranulocytosis. 
The reference cohort consisted of all people in the catchment area of all 
pharmacies included in the PHARMO RLS. 
Case definition 
Agranulocytosis was defined as severe neutropenia (5 0.5*10'/1) in an 
individual 2 years of age or older who used to have nOlmal haematological 
values, and who had symptOll1S compatible with agranulocytosis, notably fever 
and infections. Besides, cases had to comply with all of the following criteria: 
Hb ;;, 6,5 mmolll or Ht ;;, 0,32 if normochromic (men and women) 
Platelets;;, 100*10'/1 
Bone marrow aspirate or biopsy which confirmed the diagnosis, or if there 
was none: recovery of the absolute number of neutrophilic granulocytes 
within 30 days to > 1.5*10'/1. 
Exposure definition 
For every case, an index day was defined as the first day of the onset of fever 
(temperature;;, 38°C), chills or a sore throat. Furthermore, if the symptoms 
disappeared 5 days before admission or earlier, these were not taken into 
account. For every case, a risk time window was defined as the IO-day period 
preceding the index day. It was thus assumed that drug use had to be within 10 
days before the index day in order to be a potential hazard. In all cases of a 
reaction classified as agranulocytosis probable or agranulocytosis possible the 
reporting consultant was asked for permission to contact the general 
practitioner and the pharmacist of the patient in order to assess the use of 
drugs in the three months prior to admission. These data were used as exposure 
data, in combination with the data from the patient record. If 1I0t available, 
data on exposure to drugs were collected from the patients' hospital record 
only. For every drug, the legend duration was calculated by dividing the total 
number of dispensed tabletslcapsules by the prescribed daily number of 
tablets/capsules. To correct for undercompliance and carry-over effects, this 
period was multiplied by a factor 1.1 with a maximum of 14 days. Cases were 
considered exposed to all drugs for which the legend duration fell (patily) 
within the IO-day risk time window. The drug had to have been used before 
the onset of agranulocytosis. If the drug was discontinued before the index day, 
the last day of use of the particular drug had to be within the time period of 10 
days before the index day. Since the data from the reference cohort include 
only data from commuility pharmacies and not from hospital pharmacies, cases 
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who developed agranulocytosis during hospital admission (and thus probably 
due to drugs supplied by a hospital phannacy) were excluded from the study. 
For every member of the reference cohort aged 2 years or older, a random 
lO-day period was chosen in each year separately. People in the reference 
cohort were considered exposed to all drugs of which the legend duration fell 
within this lO-day period. For every drug, the legend duration was calculated 
as defined above. The average number of users in each year of the study 
period was calculated in each age and gender stratum, standardised to the 
population size in the PHARMO RLS catchment area in 1990 (n = 471,812). 
Procedures 
In 1992, a request for infonnation was sent to all hospitals where patients had 
been discharged in the years 1987-1990 with one of the principal diagnoses 
mentioned above. All physicians involved in the treatment of these patients 
received a request for an anonymized copy of the discharge summary, 
laboratory results and, if available, descriptions of bone marrow material. 
If the data received were too scanty further infonnation was requested. All 
patient data were analysed, blinded with respect to the cause of 
agranulocytosis, as follows: 
Every admission was analysed according to a predefined algorithm, and 
classified as either agranulocytosis probable, agranulocytosis possible, 
agranulocytosis Imlikelyor agranulocytosis Imclassifiable (Figure 1). A blinded 
Hematology Review Committee assessed the clinical details of those 
admissions, where the diagnosis was not straightforward. If two members 
differed in their opinion on the classification of an admission, it was discussed 
in a joint meeting of the Committee. Then, final classification was based on 
consensus (same classification by all three members) or on majority of votes in 
case of a minor discrepancy (e.g. agranulocytosis possible versus 
agranulocytosis Im/ike/y). If no agreement was obtained, the admission was 
classified as agranulocytosis IlIIclassifiable. Furthennore, a 10% random 
sample of the remainder of admissions was reanalysed by one of the members 
of the Hematology Review Committee in order to check the validity of the 
first analysis. 
An admission because of agranulocytosis was classified as severe if the 
patient developed sepsis or septic shock due to agranulocytosis. 
Data analysis 
An estimation was made of the relative risk (RR) of developing 
agranulocytosis when being exposed to a certain drug(group) compared to not 
being exposed. This was done by dividing the ratio of cases exposed (cJ) and 
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Figure 1. Model of classification by the Hematology Review Committee 
------------------------------------------ -- -I. Vedfication --------- --------- -------------------------------------- --------
Gender, date of birth and 
admission, symptoms and 
leukocyte count present? 
-
AgamrlocytosiS 
~ III/classifiable 
------ --- ------.----- ---------------II. Diagnosis ------------------------------.. -.---
+ 
- Patient 2 years or older 
- Symptomatic 
- Index day present 
+ 
- Granulocytes .:0:;: 0.5* 109/1 
- Hb ;:0: 6.5 mmol/l or HI :?:: 0.32 
- Platelets:?:: 100x109JI 
- Bone marrow aspiralelbiopsy continuing 
the diagnosis 
m: recovery of absolute number of 
neutrophils < 30 days 
-
- Granulocytes s; 0.5* 109/l 
-Rb:?: 6.5 mmoVIor Ht :?:: 0.32 
- Platelets:?: IOOx109/l 
- No bone marrow aspiratelbiopsy available 
mill: recovery of absolute llwuber of 
neutrophils < 30 days is unknown 
-
- Hb and Ht or Platelets unknown 
1 
AgranulocytosiS 
Ilnlikely 
-
-
+ 
+ 
+ 
Exc1usiollfrom 
the maill study 
Agrallulocytosis 
probable 
AgranulocytosiS 
possible 
Agralllflocytosis 
IUlc1assifiable 
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not exposed (co) to drug(group) X to the ratio of cohort members exposed (b.) 
and not exposed (bo) to this drug(group) as assessed in the PHARMO RLS 
system [20]. 
RR 
Point· estimates were calculated with their 95% confidence intervals for case-
cohort studies [20, 21]. 
The etiological fractions and excess lisks were calculated according to 
standard procedures [22]. All causes which were significantly associated with 
agranulocytosis in the univariate analysis were subsequently adjusted for age, 
gender and concomitant drug use in a stratified analysis [21]. 
Results 
In the peliod 1987-1990 there had been 923 admissions with a principal 
diagnosis coded as agranulocytosis (288.0) (n~859), functional disorders of 
neutrophil polymorphonuclears (288.1) (n~26), genetic anomalies of leukocytes 
(288.2) (n~2) and unspecified diseases of white blood cells (288.9) (n~36). To 
the request for information a reaction was received on 753 admissions (82%). 
On approximately 50% of the cases all relevant information was received (i.e. 
at least a copy of the discharge summary, and the laboratory and bone malTOW 
results). In the remainder, the hospitals were asked for additional information, 
resulting in data on 678 admissions, of which 66 concerned patients who had 
been admitted more than once. A fuliher 86 cases were excluded because of 
insufficient data (e.g. no descliption of symptoms or leukocyte counts) and 114 
were excluded, either because the patient was less than 2 years old, or had no 
symptoms on admission (i.e., agranulocytosis was discovered by coincidence). 
The remaining 478 admissions were classified as follows: agranulocytosis 
probable (n~72), agranulocytosis possible (n~36), agranulocytosis unlikely 
(n~363) and agranulocytosis III/classifiable (n~7) (Figure 2). 78 of the 108 
admissions classified as agranulocytosis probable or agranulocytosis possible 
were reactions which occurred outside the hospital and which were the direct 
reason for admission. The remaining 30 consisted either of reactions in the 
outpatient clinic or occurred inside the clinic during admission. 
Of the admissions coded as diagnosis 288.0 (agranulocytosis) 333 (74.5% of 
classified admissions) were classified as agranulocytosis unlikely (Figure 2). 
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Figure 2. Overview of study results. 
Total study population 923
1 
I 
Response 753 (82%) I 
I 
Sufficient information 592 (79% out of753) I 
I 
Age;:.: 2 years and symptoms on admission 478
1 
I 
Diagnosis code 288.0 288.1 288.2 288.9 Total 
Ullclassifiable 7 - - - 7 
Agranulocytosis III/likely 333 7 2 21 363 
[Agranulocytosis probable 72 - - - 72 
Agranulocytosis possible 35 I -
-
36 
I 
~gralllllocytOSiS probable or possible 108
1 
I 
Occurred outside hospital, transferrals excluded 75 I 
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Most of these patients had been admitted with pancytopenia or a combination 
of leukocytopenia with anemia or thrombocytopenia due to chemotherapy. 
Only the events which occurred outside the hospital and led to admission 
and which were classified as agranulocytosis probable or agranulocytosis 
possible were used in the futiher analysis, as cases occurring in the hospital 
could not be related to the exposure data acquired from community 
phannacies. 
This group consisted of 78 cases. Of this group 6 patients died (7.7%), and 
in an additional 6 patients the event was severe in view of development of 
sepsis or septic shock. Fever was present in an additional 66 patients, often 
with chills. 
Blood cultures were performed in 65 patients, of which 39 were positive. 
Bone marrow was examined in 47 patients, and in 44 confirmed the diagnosis 
agranulocytosis. In three patients the results were inconclusive. Once the cause 
of agranulocytosis was discontinued, neutrophil count recovered within 30 days 
in 43 patients, it did not recover within this petiod in eight patients, there were 
no data in 22 patients, and five other patients died before recovety of their 
neutrophil count. 
Five patients were admitted twice, two of these on separate occasions. Three 
patients, however, were transferred from one hospital to another for the same 
diagnosis. These three admissions were therefore excluded. 
After exclusion 75 cases remained, 30 men (median age 48.5 years, 25% -
75%: 32 - 67 years) and 45 women (median age 61 years, 25% - 75%: 42 - 73 
years). 
The incidence of agranulocytosis was estimated at 1.7 per million inhabitants 
in 1987, 2.2 per million in 1988, 2.5 per million in 1989, and 1.6 per million 
in 1990. 
In the cases classified as agranulocytosis probable or agranulocytosis 
possible, in which the event had been the reason for admission, the main drugs 
used prior to the index day were thiamazole (n~15), digoxin (n~12), 
prednisone (n~lO), sulphasalazine (n~9), co-ttimoxazole (n~8), paracetamol 
including combinations (n~8), furosemide (n~6), hydrochlorothiazide with 
potassium-spating drugs (n~6), levothyroxine (n~5), ibuprofen (n~5), 
acenocoumarol (n~5), propranolol (n~5), and oxazepam (n~5). The prevalence 
of use in the reference cohort (catchment area of PHARMO RLS) is also given 
in Table I for drug groups and in Table 2 for the individual drugs most 
fi'equently used prior to agranulocytosis. The relative tisks of hospital 
admissions because of agranulocytosis, adjusted for age, gender, and 
concomitant drug lise, are also shown in Table I and Table 2 respectively, as 
well as the etiological fi'action and excess risk for those drugs for which the 
adjusted relative risk was significantly elevated. 
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Table 1. Drug-associated agranulocytosis: drugs used prior to index day in 1987-1990 (n~75), drug groups, nwnber of users standardised 
to the population in 1990. The risk of agranulocytosis expressed as relative risk with 95% confidence interval (adjusted for age, gender 
and concomitant drug use). etiological fraction, and excess risk per 1,000,000 persons during 10 days exposure. 
Drug groups Number Number of users Adjusted relative risk (95%-CI) Etiological Excess 
of cases in PHARMO RLS fraction risk 
Thyreostatics 17 752 114.8 (60.5 - 218.6)" 0.23 4.85 
Diuretics 17 22095 2.3 (1.2 - 4.3/ 0.13 0.06 
Benzodiazepines 15 29824 1.5 (0.8 - 2.9) 
Glucocorticoids 12 5011 8.2 (4.2 - 16.0/ 0.14 0.34 
NSAID's 12 20220 2.5 (1.3 - 4.9/ 0.10 0.08 
ParacetamoI, including combinations 8 14003 2.4 (1.1 - 5.2/ 0.06 0.07 
Acetylcysteine!bromhexinelcarbocisteine 7 7745 3.9 (1.6 - 8.8)' 0.07 0.15 
Coumarins 7 6547 2.7 (1.1 - 6.5/ 0.06 0.09 
Penicillins 6 10697 3.1 (1.3 - 7.9/ 0.05 0.11 
Salicylates 5 4748 3.6 (1.3 - 9.3/ 0.05 0.14 
Calcium antagonists 5 5444 1.9 (0.7 - 5.1) 
Nitrates 5 5499 1.9 (0.6 - 4.9) 
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Table 2. Drug-associated agranulocytosis: drugs used prior to index day in 1987-1990 (n=75), individual drugs, number of users 9 w 0 standardised to the population in 1990. The risk of agranulocytosis expressed as relative risk with 95% confidence interval (adjusted for ~ 
age, gender and concomitant drug use), etiological fraction, and excess risk per 1,000,000 persons during 10 days exposure. ~ 
'C 
Individual drugs Number Number of users Adjusted relative risk (95%-CI) Etiological Excess 
of cases in PHARMO RLS fraction risk 
Thiamazole IS 315 230.9 (120.4 - 453.5)" 0.20 10.13 
Digoxin 12 5108 5.9 (2.8 - 12.6)" 0.13 0.23 
Prednisone 10 1587 19.9 (10.1 - 43.7)' 0.13 0.91 
Sulphasa1azine 9 523 74.6 (36.3 - 167.8)' 0.12 3.57 
Co-trimoxazole 8 1952 25.1 (11.2 - 55.0)" 0.10 1.19 
Clomipramine 4 714 20.0 (6.1 - 57.6)" 0.05 0.99 
Dipyrone with analgesics 2 325 26.4 (4.4 - 111.1)" 0.03 1.36 
Carbimazole 2 376 16.7 (2.6 - 69.7)' 0.03 0.84 
Carbamazepine 2 1590 5.9 (1.0 - 24.4) 
Amitriptyline 2 1266 4.0 (0.7 - 16.9) 
Promethazine 2 3024 3.6 (0.6 - 15.1) 
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Discussion 
This study was perfonned in order to examine the dmg-related causes of 
hospital admissions because of agranulocytosis in The Netherlands, with a 
population based case-cohort design. 
Although the misclassification might seem to be very high, excluded 
admissions mostly pertained to diagnoses closely related to agranulocytosis. 
These admissions were all excluded from our study, since it concerned most of 
the time pancytopenia, or a combination of agranulocytosis with anemia or 
thrombocytopenia, and the responsible dmgs were not dispensed by a 
community phannacy. Obviously, the classification of agranulocytosis of the 
Dutch Centre for Health Care Infonnation contained a large number of 
admissions which were not our topic of interest. 
The number of hospitalisations in the Netherlands due to agranulocytosis has 
increased during the past years. In 1991, an increase was noted in the number 
of admissions to Dutch hospitals because of agranulocytosis. Whereas in 1987 
there were 182/1,502,018 admissions because of agranulocytosis, this number 
more than doubled to 393fI,582,458 in 1994 (Figure 3). Basrod on our study, 
Figure 3 
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no specific product could be held responsible for this surge in admissions. 
However, the number of patients admitted because of agranulocytosis due to 
chemotherapy has risen throughout these years, indicating that these are 
probably the responsible agents. 
In our study, many data were required for the clinical validation of 
agranulocytosis Cas e.g. laboratory and bone marrow results). Although in 82% 
of admissions a response was received, not all included the information 
required for classification. Moreover, only admissions of patients with 
community acquired agranulocytosis could be used for the relative lisk 
estimations, as in-hospital exposure data were not available. Since there 
appeared to be a large group of patients who developed agranulocytosis due to 
chemotherapy, only a small group of patients was left for analysis. 
In this study, we were not able to assess an incidence rate of leucopenia as 
not all patients will have been admitted. It is likely, however, that few 
symptomatic cases will have been missed and that our study gives a fairly 
accurate estimation of the cumulative incidence of symptomatic agranulocytosis 
in the community outside the hospital. It should be noted that patients could 
have been admitted with agranulocytosis and coded othenvise in the regish'y of 
the Dutch Centre for Health Care Information. In order to assess false-negative 
misclassification, we added three diagnosis codes which could have included 
cases of agranulocytosis, and found only one possible case. It is still possible, 
however, that cases of agranulocytosis were coded othenvise, although this 
seems to be unlikely. Thyreostatic drugs had the highest relative risk and 
excess risk of drug-associated agranulocytosis, but also co-mmoxazole, 
sulphasalazine, clomipramine and dipyrone combined with analgesics were 
associated with high risk estimates. 
Obviously, the cumulative incidence of agranulocytosis is much higher 
during admission in the hospital, especially in those specialized on cancer 
treatment, but in the absence of good drug exposure data concerning inpatients 
this cumulative incidence is difficult to estimate. We were interested, however, 
in the increase in admissions because of agranulocytosis to causes encountered 
outside the hospital. Although the PHARMO RLS exposure data are a sample 
of the drug use in the Dutch population, these data are good estimators of drug 
exposure [23]. Another reason for choosing the PHARMO RLS system as a 
source of exposure data is that these dispensing data are the only available data 
on an individual patient level in the period 1987 - 1990. 
For this study we considered several types of epidemiologic designs. 
Because of the low incidence of agranulocytosis, we did not consider a COhOli 
shldy as a useful approach. Case-control studies are very suitable for studying 
rare diseases. We had several reasons for not using a case-control design. First, 
recall bias would have been introduced into the study. As agranulocytosis is an 
impressive type of event that patients are not likely to forget, it would not have 
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been easy to find controls subject to the same recall of exposure as cases. 
Second, as drugs are a well-known cause of agranulocytosis, physicians might 
inquire more insistently about drug use in the index than in the control group. 
Third, although agranulocytosis is considered to be a rare disease, the low 
population exposure prevalence of some drugs (e.g. thyreostatics) could 
consequently have meant that none of the controls would have been exposed to 
those drugs. Therefore, we used a case-cohort design, in which the cases were 
all patients admitted because of agranulocytosis in The Netherlands in the 
period 1987 to 1990 and the control cohort was a reference cohort of the 
Dutch population. 
Theoretically, our analysis could have been adversely influenced by two 
issues. First, bias or confounding might have played a role. Selection bias 
might occur if agranulocytosis to one drug is more severe than agranulocytosis 
to another, or if patients with agranulocytosis to a particular drug are admitted 
more readily than patients with agranulocytosis to another drug. However, 
there are no reasons to believe that agranulocytosis to orally administered 
thiamazole or sulphasalazine has a worse prognosis than agranulocytosis to 
other orally administered drugs. Hence, this will mean that the proportion of 
community acquired cases of agranulocytosis which leads to admission is more 
or less the same for these drugs. Information bias might result if doctors who 
anticipate an increased risk of agranulocytosis perform more blood tests. This 
could occur, for instance, in patients on thyreostatic agents as these are a well-
known cause of agranulocytosis. As all cases were symptomatic, however, this 
is not a likely explanation because symptomatic agranulocytosis will almost 
always lead to admission. Information bias by differential recall of drug use by 
patients (,recall bias') was not a problem as the information came from 
automated pharmacies and had been gathered before disease onset. In those 
patients in whom drug use could be checked in pharmacy data or general 
practitioner's records, 85% of drugs mentioned in the hospital data could be 
confirmed. Although it was possible to obtain the filling data on most cases, it 
was virtually impossible to get these data over a longer episode than the risk 
period. Therefore, dose and duration related risk estimates could not be 
obtained. Confounding is unlikely, as apart from drugs there are few 
independent risk factors for agranulocytosis, and we adjusted for age, gender, 
and concurrent drug use. 
The second issue is that the reference cohort was not a random sample from 
the total study base. It is logistically impossible to take a random sample fi'om 
the total study base of all inhabitants in The Netherlands. Instead of this we 
used a representative sample of community pharmacies, located in different 
parts of the country to minimize the role of regional differences in prescribing 
by medical practitioners. Thus, we do not believe that the exposure in the 
reference cohort differs substantially from the exposure in the total study base, 
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especially not as the vital statistics concerning age and gender of the reference 
cohort were the same as that of the population in The Netherlands [23]. 
In the lAAAS the overall incidence of community acquired agranulocytosis 
was estimated at 3.4 per miIlion inhabitants per year [24], which is slightly 
higher than the 1.6 to 2.5 per million inhabitants per year found in our study. 
The lAAAS has been heavily debated, since bias was thought to play a role 
[15 - 18]. One of the difficulties was, that the rate ratio regarding dipyrone 
varied between regions from 0.8 to 23.7 [4]. The researchers could not explain 
this result, and thought it could be related to the differences in use of dipyrone 
in these regions: the risks were high in regions where the drug was not used 
very often, and low in those regions where use was common. Insofar as we are 
aware of, our study is the first which includes all cases of admitted 
agranulocytosis from a whole country. Our results were comparable to the 
IAAAS with regards to the elevated risks found for thyreostatic drugs and 
dipyrone, although the absolute number of cases to dipyrone was smaIl. For 
thyreostatics a relative risk of 102 was found in the lAAAS (excess risk 6.3 
per million users during one week of exposure) [5], which is comparable to the 
relative risk of 11 5 (excess risk 4.9 per million users during 10 days of 
exposure) found in the current study. There were not enough data to compare 
the different thyreostatics, but from the figures in the IAAAS paper one can 
deduct that also in this study the risk for thiamazole seems to be higher than 
for carbimazole [5]. Since carbimazole is converted to thiamazole in vivo, this 
higher Iisk is difficult to explain. With regards to anti-infective agents, an 
elevated relative risk was found for co-tIimoxazole (12, excess Iisk 1.6 per 
million with two weeks exposure) and the macrolides (excess risk 7.1 per 
million) [6]. Cardiovascular drugs found to have an elevated relative risk were 
propranolol (relative risk 2.5, excess risk 0.1 per million with one week 
exposure), digoxin and acetyldigoxin (relative risk 2.5 and 9.9 respectively, 
excess risk o. I and 0.3) [8]. 
Two main types of mechanisms of drug-induced agranulocytosis have been 
recognized: the first is a dose-related toxic reaction (e.g. phenothiazines, 
antithyroid drugs, and chloramphenicol), and the second is an immune or 
allergic reaction (e.g. dipyrone). For most drugs it is unclear by which 
mechanism agranulocytosis is induced. Several drugs found in this study to 
have an elevated relative risk have been associated with agranulocytosis in the 
medical literature, including diuretics (e.g. chlorthalidone), antithyroid drugs 
(carbimazole, thiamazole, and propylthiouracil), peniciIlins, indomethacin, 
acetaminophen, dipyrone, benzodiazepines, antidepressants (e.g. amitIiptyline), 
sulphasalazine, co-trimoxazole, carbamazepine, and phenothiazines [I]. For 
several other drugs, e.g. coumarins, digoxin, and prednisone this was not the 
case, although in the IAAAS also an elevated relative risk was found for 
digoxin and prednisone, for which the authors had no explanation. As in our 
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patients agranulocytosis disappeared despite continuation of these drugs, the 
association with these two drugs is probably not causal. 
In conclusion, we found a slightly lower cumulative yearly incidence of 
community-acquired agranulocytosis in The Netherlands than was found in the 
IAAAS. In our study, thyreostatic drugs, co-trimoxazole, sulphasalazine, 
clomipramine and dipyrone combined with analgesics were associated with the 
highest risks of agranulocytosis. 
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Part V 
General discussion and summary 

General discussion 

Gel/era! discussion 
The nationwide, population based case-cohort design 
This thesis concerns the quantitative aspects of adverse drug reaction issues 
encountered at the Drug Safety Unit of the Inspectorate for Health Care in The 
Netherlands (DSU), and focuses on two serious adverse events which are 
frequently associated with drugs, namely anaphylaxis and agranulocytosis. The 
data from the DSU were not suitable for estimating incidences or relative risks 
of adverse events and their suspected causes. Therefore we looked for ways to 
investigate these rare adverse events. The main problem was, that not only were 
the adverse events rare, also the suspected drugs were not widely used. Cohort 
studies are suitable for studying rare exposure, but not rare outcome, and case-
control studies are suitable for studying rare outcome, but not rare exposure. In 
this discussion, we will elaborate on our choice for a nationwide, population based 
case-cohort design. 
The theoretical considerations concerning the nationwide, population based 
case-cohort design have been discussed in chapter 7. Why did we choose this 
design for the studies on anaphylaxis and agranulocytosis? In other words, what 
are the advantages and limitations of this approach? It is important to emphasize 
that although there are clear theoretical differences between a cohort, case-control 
and case-cohort design, all can be used to estimate relative risks. Even though a 
case-control study is more vulnerable to bias than a prospective cohort study and 
is (unless it is population based) less suitable for incidence assessment of disease, 
all designs may give valid risk estimates. Population based cohort studies on a 
nationwide scale have been performed in The Netherlands when studying rare 
exposure such as ibopamine [I) and acitretine [2). On a similar scale, population 
based case-control studies have been performed on rare diseases such as GuiIlain-
Barre syndrome [3) and primary pulmonary hypertension [4]. Here, the discussion 
focuses on the comparison between the current population based case-cohOli 
design, and population based cohort and case-control designs when studying rare 
drug-associated events to rarely used drugs. 
Obviously, a cohort study was not feasible when studying these rare events 
because this would require such a large cohort that the cost would be enormous. 
Hence, the most reasonable choice was between a population based case-cohOli 
design, and a study with a population based case-control design with the same 
sample of cases. 
Ideally, every epidemiological study is valid,precise and ejJiciellf. In other words: 
the risk estimates should be correct, the confidence intervals narrow (indicating 
that when the study is repeated, the risk estimates largely remain the same), and 
the study should not be unduly expensive or of long duration. Also impOliant is 
the external validity, or gel/eralisability of the study. Below, we will discuss the 
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value and shortcomings on each of these items of the case-cohort and case-control 
designs respectively. The results of this discussion are summarised in Table I. 
The validity of a study may be endangered by chalice, bias and COlif'0lllldillg. 
Although chance findings can never be excluded, the possibility that a 
significantly increased risk estimate is explained solely by chance is reduced to 
5% by convention and use of statistical techniques. The aspect of chance will not 
be dicussed in our comparison of the case-control and case-cohort design. 
Bias is usually divided into selection bias (or sample distortioll bias), and 
inf0rmatioll bias. Selection bias is an error due to systematic differences in 
characteristics between those who are selected for the study and those who are not 
[5]. If identification of study subjects takes place on the basis of outcome, this 
occurs only when these systematic differences are related to the exposure of 
interest. In the current examples, both a case-cohort and a case-control design 
would have required the same sample of cases, obtained via all general and 
university hospitals in The Netherlands. In both case-cohort studies in this thesis, 
most clinical data were obtained anonymously, without identifying patients or 
physicians, or sometimes even hospitals. In a case-control study, however, we 
would have had to contact the hospital and the physician to obtain controls from 
the same hospital or outpatient setting. This could have resulted in a much larger 
non-response than the approximately 15% non-response which we encountered in 
the case-cohort studies. Moreover, the lower response rate in a case-control study 
could have been biased, as in the study of anaphylaxis, for instance, the role of 
glafenine was a well-known topic. A selective response in cases of glafenine-
associated anaphylaxis could have inflated the relative risk estimations. ApaIt 
from selective response in obtaining clinical data from cases, the choice of a 
control group would have been a problem. It is very difficult to choose a 
consistent hospital control group of persons who do not have a higher or lower 
chance of using the drugs of interest. Ideally, one should choose community 
controls, but this would further have jeopardized the response rate, as it would 
have required sequential permission of hospitals, internists, general practitioners 
and patients. In the case-cohort design, however, community controls were 
included in the reference cohort. 
Also, selection bias could have occurred if physicians admitted patients because 
they were aware of the fact that their patients had used the exposure of interest 
("refen'al bias") [6]. In both study types, there would have been a similar 
possibility that referral bias had played a role, as both would have used the same 
sample of admitted cases. Such selection bias was, however, unlikely. In case of 
anaphylaxis, a general practitioner will refer a patient on the basis of severity, 
irrespective of the cause. Also agranulocytosis is a serious event, warranting 
admission to a hospital. In both study types, patients who were treated at home 
or died at home did not enter the case group. We thought it unlikely that many 
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patients would be treated at home for such serious events as anaphylaxis or 
agranulocytosis, and as distances are small in The Netherlands it seemed unlikely 
that patients would have died at home from these illnesses without having been 
admitted to a hospital. 
In the case of agranulocytosis, when regular blood counts are performed 
because this is advised in the product information of a drug, this could lead to 
Itdetection bias", For this reason, we restricted our analysis to symptomatic cases, 
thereby excluding "cases" which were the result of such routine assessments. This 
feature would be a problem in both the case-control and the case-cohOli design. 
Although there is essentially no difference in the potential bias in the selection of 
cases for both study designs, the selection of controls in a case-control design may 
be biased, whereas this is not a problem in the case-cohOli design as described in 
this thesis. 
Nondifferential misclassification of disease in the data from the Dutch Centre 
for Health Care Information could have occurred [7]. In order to account for 
positive misclassification, validation of the admissions took place. We tried to 
account for negative misclassification by including several admission diagnoses 
which could have included cases of anaphylaxis or agranulocytosis, and did not 
find many misclassified admissions. Bias among the admissions selected for the 
study might have taken place if patients with an adverse reaction to one paliicular 
drug were coded as the adverse reaction, and patients with the same adverse 
reaction to another drug were coded differently, e.g. agranulocytosis as 
leukopenia, and anaphylaxis as urticaria. We did not find evidence to support this. 
Informatioll bias is a flaw in measuring exposure or outcome that results in 
differential quality (accuracy) of information between compared groups [5]. 
Illfonllatioll bias might occur, for instance, when patients with a disease 
remembered more about their drug use than healthy controls ("recall bias") [6]. 
In the case-cohort design, recall bias was not a problem as the exposure histories 
of the control group were gathered from the sample of pharmacies before disease 
onset. Although this was not a random sample of pharmacies, several comparisons 
showed us that the drug exposure data were representative of drug use in The 
Netherlands. In order to account for differences in prescription behaviour, data 
fi'om several parts of The Netherlands were included. Since all pharmacies in the 
six PHARMO cities are covered by the database, changing from one pharmacy 
to another does not affect the data in the database. In a case-control study, 
however, such data would not have been available, as pharmacy data on many of 
the cases and controls would no longer be available, due to the time lag between 
occurrence and registration in the data base of the Dutch Centre for Health Care 
Information. Both from the point of view of the vulnerability to selectioll bias and 
illformatioll bias, the case-cohort has advantages over the case-control design 
when considering the current topics of interest. 
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COIifounding occurs when another factor than the exposure of interest is an 
independent risk factor for the outcome of interest and also associated with the 
exposure of interest, without being an intermediate step in the causal pathway 
[6,7]. Here, a case-control may have advantages over a case-cohort design, as data 
on the presence or absence of all potential risk factors can be obtained quite 
easily. In the case-cohort design, information about such other risk factors are 
usually not available on all members of the reference cohort. In the current 
examples, i.e. anaphylaxis and agranulocytosis, this was not a problem of 
impOliance. First, because both diseases are mostly caused by drugs and have few 
other independent risk factors. Second, because these other known independent 
risk factors are not associated with the drugs that cause anaphylaxis and 
agranulocytosis respectively. On the other hand, unless data on other risk factors 
are gathered from the reference cohort, this means that the value of the current 
nationwide population based case-cohort design is limited to diseases with a high 
drug-attributed etiological fraction. 
Table 1. Advantages and limitations of case-control and case-cohort designs. 
Suitable for studying rare disease 
Suitable for studying rare exposure 
Can examine multiple exposure 
Probability of high response rate 
Controls can be used for several studies 
Subject to recall bias 
Subject to selection bias 
Co-factor/confounder data available 
Efficient 
Well suited for evaluation of disease with long latent period 
Incidence rates computable if population based 
Generalisability 
Case-control 
+ 
+ 
+1-
+1-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Case-cohort 
+ 
+ 
+ 
+ 
+ 
+1-
+1-
++ 
+ 
+ 
+ 
The precision of a study is reflected in the 95%-confidence intervals. The 
precision may be endangered by too few cases or controls. As we were not able 
to increase the number of well-documented (admitted) cases of both rare events, 
we needed a large reference group. In the study on anaphylaxis, for instance, we 
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would have had a fair chance that none of the controls in a case-control study 
would have been exposed to glafenine, as its use had strongly declined. For this 
reason, a case-cohort study had obvious advantages. 
The efficiellcy of an epidemiological study tells us how fast, and at what price 
a study of sufficient validity and precision can be performed. From the point of 
view of efficiency, the case-cohort study was both faster and cheaper than a case-
control study. It would have cost time and money to obtain peimission for the 
study from hospitals, physicians, and patients, and drug exposure data from the 
control group itself in a case-control study. We were, however, able to work with 
anonymized clinical data on the cases alone in the case-cohort study, and had 
exposure data of the reference cohort already available. 
The gelleralisability (external validity) of a study does not so much depend on 
whether the sample is representative of the total population, but more on whether 
the results can be extrapolated to the total population [7]. As we included all 
admitted symptomatic cases in The Netherlands, this applies to both the 
anaphylaxis and agranulocytosis study, irrespective of the question as to whether 
we would have chosen a case-control or a case-cohort design. 
Conclusion 
Both the validity, preCISlOn and efficiency of the case-cohort design were 
sufficient for studying the outcomes of interest. This type of design may be velY 
useful when there is a need to study serious but rare diseases to rarely used drugs, 
especially when rapid results are required, as is often the case when problems 
arise shortly after the introduction of new pharmacological entities. There are, 
however, also limitations to this approach. The main limitation is that, except for 
age and gender, no data are available on non-drug-related risk factors. This 
limitation can be dealt with, however, by obtaining such data at regular intervals 
from random samples from the reference cohOlt. 
Also, it is only possible to investigate adverse reactions, which are so serious 
that they will lead to hospital admission, since hospital admission data are used. 
It is not always possible to estimate the incidence of adverse reactions, since those 
patients that have not been admitted to the hospital (but were treated at home or 
died at home) are not included in the study, and all adverse reactions which were 
not coded as a principal diagnosis, but as an additional diagnosis (mostly adverse 
reactions due to drugs that were given in the hospital) are not included as well. 
However, when dealing with an adverse reaction which is so serious that it will 
always lead to hospital admission, one can assume that no cases have been 
missed, and in this situation it is possible to estimate the incidence. 
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In conclusion, the case-cohort design has proved to be a useful design for 
studying rare events with a high attributable risk of drugs, such as anaphylaxis or 
agranulocytosis. 
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Adverse drug reaction monitoring started to develop in the nineteen-fifties, but it 
was strongly stimulated by the thalidomide disaster in 1961. Until recently, 
adverse drug reaction monitoring has been performed by the national reporting 
centres in different counnies, which also pool summarised data at the World 
Health Organisation Collaborating Centre for International Drug Monitoring in 
Uppsala. Most important data, however, used to come from the medical literature, 
but some centres made a substantial contribution to the detection of unknO\vn 
adverse reactions. Pharmaceutical firms have their own adverse reaction 
registration systems. Several problems have been encountered with adverse drug 
reaction monitoring systems, the main problem being selective recognition and 
reporting of suspected adverse reactions. Another major problem is, that sales 
figures on drugs are not always available. In clinical trials, the most frequent 
adverse events are usually detected, but rare adverse events are mostly not 
discovered, since only small numbers of patients are involved. Also, the elderly, 
children and pregnant women, use of co-medication, co-existence of other 
diseases, and longterm use are mostly not examined in clinical trials. The 
increasing availability of computers and large databases has made it possible, not 
only to monitor data on large numbers of patients, but also to process these data 
fairly easily. This has stimulated the rapid advance of epidemiology, and recently 
the development of phatmacoepidemiology as a subspeciality, encounteling 
several specific problems when studying drug use, adverse reactions to drugs, and 
other drug effects. In chapter 1, the problems in assessing drug safety, and the 
systems and methods for pharmacoepidemiology are discussed. 
The scope of this thesis was to examine the usefulness of the nationwide 
population based case-cohort design when studying rare, but serious, adverse 
events to rarely used andlor newly marketed drugs. Therefore, attention was 
focused on two adverse reactions which are both rare and often caused by drugs, 
i.e. anaphylaxis and agranulocytosis (chapter 2). 
The studies in this thesis were started because of a problem encountered at the 
Drug Safety Unit of the Inspectorate for Health Care in The Netherlands, formerly 
the Netherlands Centre for Monitoring of Adverse Reactions to Drugs. Since 
1974, a large number of reports on glafenine-associated anaphylaxis were 
received, reaching a peak in 1979. The problem was that it was impossible to 
prove solely on the basis of reporting figures, that the number of glafenine-
associated anaphylactic reactions was indeed higher than the number of 
anaphylactic reactions associated with other analgesics. Due to the publicity on 
glafenine and its adverse events, it was conceivable that glafenine-associated 
adverse events were reported relatively more often than adverse events due to 
other drugs. This was also emphasised by the marketing authorization holder, who 
maintained that the large number of reports was based solely on reporting bias. 
Therefore, a study was performed on all reports on drug-associated anaphylaxis 
made in the past 20 years to the Drug Safety Unit. This study not only showed 
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that slightly more than one third of all reports on anaphylaxis were associated 
with glafenine, but also, that there was a large number of reports on 
trimethoprim-associated anaphylaxis, which have been described separately as a 
case series (chapter 3). The slndy on all reports of drug-associated anaphylaxis is 
described in chapter 5. Since this slndy gave rise to alarming figures on glafenine-
associated anaphylaxis, a suitable slndy design was sought to cope with the 
problem of reporting bias. 
Another problem at the Drug Safety Unit with a rare, but serious, adverse event 
pertained to drug-associated agranulocytosis, and mainly agranulocytosis due to 
antidepressants. A case of agranulocytosis associated with trazodone was repOlted, 
and is described in chapter 4. There were also reports and slndies in the literalnre, 
suggesting that mianserin caused agranulocytosis fairly often, but the number of 
epidemiological slndies substantiating this were scanty. In the eighties, a large 
case-control Slndy had been performed, the International Agranulocytosis and 
Aplastic Anemia Slndy, but in this period mianserin had not yet been widely 
marketed. Therefore, we started with a review of all reports on drug-associated 
agranulocytosis (chapter 6). This showed that next to dipyrone, mianserin was 
most often reported as a suspected cause of drug-induced agranulocytosis. Again 
the problem of reporting bias was thought to playa role, and a suitable slndy 
design for this problem was needed as well. 
The main problem encountered was not only that anaphylaxis and 
agranulocytosis are rare diseases. In the case of glafenine the sales figures had 
declined dramatically, and in the case of mianserin the drug, being an 
antidepressant, had not been sold on such a large scale. Thus, the exposure to 
these drugs was rare as well. Cohort slndies are suitable for slndying rare 
exposure, but not rare disease, and in general case-control slndies are suitable for 
slndying rare disease, but not rare exposure. Kupper et aI., Miettinen and Prentice 
had published about a case-cohort slndy as an efficient design to reduce the 
number of subjects for whom covariate data are required. This is especially 
efficient if the processing of raw materials takes a lot of time. In this silnation, 
for different reasons, the case-cohort design seemed to be an efficient method to 
slndy drug-associated anaphylaxis and agranulocytosis. A data base concerning 
data on morbidity was already available (the Dutch Centre for Health Care 
Information), as was a database concerning data on exposure in a sample of the 
Dutch population (the PHARMO RLS system). A nationwide population based 
case-cohort design was therefore used. The theoretical considerations concerning 
this design are described in chapter 7. In short, the exposure in people with the 
disease ("cases") is compared to the exposure in a reference cohort taken from the 
total Dutch population. 
The slndy on drug-associated anaphylaxis performed with this case-cohort 
design is described in chapter 8. An elevated relative risk was not only found for 
glafenine, but also for amoxycillin, penicillins in general, and the group of 
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analgesic drugs. The risk of anaphylaxis to glafenine relative to analgesics, 
however, was still significantly elevated. This study was mainly responsible for 
the withdrawal of glafenine fi'om the market in a large number of countries in 
1992. 
Next, a case-cohort study on drug-associated agranulocytosis was perfOlmed. 
This study did not show a large relative risk for mianserin, but it did show an 
elevated risk for thyreostatics, sulphasalazine, and non-steroidal anti-inflammatory 
drugs (chapter 9). The results from this study were mainly similar to those found 
in the International Agranulocytosis and Aplastic Anemia Study, but higher 
relative dsks and risk differences were found for thyreostatic agents and dipyrone. 
In the final discussion (chapter 10), the advantages and limitations are discussed 
of the nationwide population based case-cohort design for pharmacoepidemiology. 
Advantages are that there is no recall bias, less risk of selection bias than in a 
case-control study, and that the study design is suitable for studying rarely used 
drugs. The main limitation is that, with the exception of age and gender, there are 
no data on other risk factors than drug use. A solution would be to collect such 
data at regular intervals in samples fi'om the reference cohott. Another limitation 
is the fact that it is only possible to estimate the incidence of adverse reactions 
that are so serious that these will always lead to hospital admission. 
It is concluded that the nationwide population based case-cohort design is 
relatively quick and cost-effective when assessing the drug-associated risks ofmre 
but serious adverse events with a high drug-attributed etiological fraction. 
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Samenvalfing 
Het systematisch registreren van bijwerkingen van geneesmiddelen begon in de 
jaren '50, en werd sterk gestimuleerd door de thalidomide (Softenon"J affaire in 
1961. Tot op heden wordt de registratie van gemelde bijwerkingen in diverse 
landen gehouden door de nationale overheden, die tevens een samenvatting van 
hun data gezamenlijk onderbrengen bij het "Collaborating Centre for International 
Drug MonitOling" van de Wereld Gezondheids Organisatie in Uppsala. De 
belangrijkste gegevens over bijwerkingen van geneesmiddelen komen echter nog 
steeds uit de medische literatuur, hoewel enkele centra een substanticle bijdrage 
leverden aan het ontdekken van onbekende bijwerkingen. Farmaceutische 
bedrijven hebben hun eigen registratiesysteem voor bijwerkingen. 
Registratiesystemen voor bijwerkingen hebben diverse tekOlikomingen, met name 
onderrapportage, selectieve herkenning en melding van effecten die ten onrechte 
als bijwerking werden gekenschets!. Een ander groot probleem is dat betrouwbare 
gegevens over het daadwerkelijk gebruik van geneesmiddelen doorgaans 
ontbreken. In klinisch onderzoek voorafgaand aan registratie worden de frequentst 
voorkomende bijwerkingen meestal ontdekl, maar zeldzame bijwerkingen nie!. Dit 
komt door de beperkle omvang van klinisch onderzoek. Bovendien worden 
ouderen, kinderen en zwangere vrouwen doorgaans van dit onderzoek uitgesloten, 
en wordt de rol van comedicatie, nevenaandoeningen en langdurig gebruik meestal 
niet onderzocht in klinisch onderzoek. De toenemende beschikbaarheid van 
computers en grote databestanden heeft het mogelijk gemaakt om niet aileen grote 
aantallen pationten te volgen, maar ook om deze data vrij gemakkelijk te 
venverken. Deze ontwikkeling is een belangrijke stimulans voor farmaco-
epidemiologisch onderzoek gebleken. In de farmaco-epidemiologie doen zich 
enkele problemen voor, die kenmerkend zijn voor het bestuderen van 
geneesmiddelengebruik, bijwerkingen van geneesmiddelen, en andere effecten van 
geneesmiddelen. In hoofdstuk I zijn de problemen besproken die zich voordoen 
bij het vaststellen van de veiligheid van geneesmiddelen, en de systemen en 
methoden voor farmaco-epidemiologisch onderzoek. 
Het doel van dit proefschrift was de bruikbaarheid te onderzoeken van een 
landelijke case-cohort studie opzet bij het bestuderen van zeldzame, maar ernstige 
bijwerkingen van geneesmiddelen die weinig gebruikt worden en/of recent op de 
markt zijn gekomen. Hiertoe werd de aandacht gericht op twee bijwerkingen die 
beiden zeldzaam zijn en vaak veroorzaakl worden door geneesmiddelen, namelijk 
anafylaxie en agranulocytose (hoofdstuk 2). 
De studies in dit proefschrift werden opgezet vanwege een probleem waannee 
het Bureau Bijwerkingen Geneesmiddelen van de Inspectie voor de 
Gezondheidszorg geconfronteerd werd. Sinds 1974 werd een groot aantal 
meldingen ontvangen van anafylactische reacties toegeschreven aan het gebruik 
van glafenine, waarbij een piek was bereikt in 1979. Het probleem was dat het 
onmogelijk was om aileen op basis van het aantal meldingen aan te ton en, dat de 
frequentie van anafylactische reakties door glafenine inderdaad hoger was dan het 
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aantal anafylactische reakties door andere analgetica. Door de publiciteit over de 
bijwerkingen van glafenine bestond de mogelijkheid dat bijwerkingen 
toegeschreven aan glafenine relatief vaker gemeld zouden worden dan 
bijwerkingen toegeschreven aan andere geneesmiddelen. Dit werd ook door de 
fabrikant benadtukt, die van mening was dat het grote aantal meldingen gebaseerd 
was op selectief melden. Derhalve werd een studie verricht naar alle bij de 
Inspectie voor de Gezondheidszorg gemelde gevallen van anafylaxie door 
geneesmiddelen in de afgelopen 20 jaar. Deze studie liet niet alleen zien dat iets 
meer dan een derde van alle meldingen betreffende anafylaxie toegeschreven 
waren aan glafenine, maar ook dat er een groot aantal meldingen waren over 
anafylaxie toegeschreven aan trimethoprim, welke laatste serie 
ziektegeschiedenissen apart zijn beschreven in hoofdstuk 3. De studie over alle 
meldingen van anafylaxie toegeschreven aan geneesmiddelen is beschreven in 
hoofdstuk 5. Gezien de omvang van het aantal meldingen van anafylaxie 
toegeschreven aan glafenine, werd een geschikte studie opzet gezocht om het 
probleem van het selectieve melden te ondervangen. 
Een ander probleem op het gebied van zeldzame, maar ernstige bijwerkingen 
betrof agranulocytose door antidepressiva. Een voorbeeld hiervan was een melding 
van agranulocytose toegeschreven aan trazodone (hoofdstuk 4). Er waren ook 
meldingen en studies in de literatuur die suggereerden dat mianserine vrij vaak 
agranulocytose veroorzaakt, maar er waren weinig epidemiologische studies die 
dit konden onderbouwen. In de jaren '80 was een grote case-control studie 
velTicht, de Internationale Agranulocytose en Aplastische Anemie Studie, maar in 
deze periode werd mianserine nog betrekkelijk beperkt gebtuikl. Eerst werd een 
overzicht gemaakt van alle meldingen van agranulocytose toegeschreven aan 
geneesmiddelen (hoofdstuk 6). Afgaand op de meldingen werden dipyrone en 
mianserine het vaakst als verdachte oorzaak van agranulocytose door 
geneesmiddelen benoemd. Opnieuw echter leek het probleem van selectief melden 
een rol te spelen, en een geschikte studie opzet voor dit probleem was daarom ook 
belangrijk. 
Het probleem was niet alleen dat anafylaxie en agranulocytose zeldzame ziekten 
zijn. In het geval van glafenine waren de verkoopcijfers sterk afgenomen, terwijl 
mianserine, een antidepressivum, op betrekkelijk beperkte schaal werd toegepasl. 
Derhalve was het gedeelte van de bevolking dat deze geneesmiddelen gebtuikte 
ook klein. Cohort studies zijn geschikt voor het bestuderen van zeldzaam 
toegepaste geneesmiddelen (expositie), maar niet van zeldzame ziekten, en in het 
algemeen zijn case-control studies geschikt voor het bestuderen van zeldzame 
ziekten, maar niet van zeldzaam toegepaste geneesmiddelen. Kupper et aI., 
Miettinen en Prentice hadden in de literatuur gesuggereerd dat een case-cohort 
studie opzet een efficiente aanpak vonnt wanneer het nodig is het aantal patienten 
waarover gegevens nodig zijn te beperken. Dit is met name efficient als het 
verkrijgen van aanvullende gegevens veel tijd kosI. Om diverse redenen leek in 
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deze situatie de case-cohort studie opzet een efficiente methode om anafYlaxie en 
agranulocytose door geneesmiddelen te bestuderen. Een gegevensbestand met 
betrekking tot morbiditeit was al beschikbaar (SIG ZorginfOlmatie), evenals een 
gegevensbestand met betrekking tot gegevens over expositie in een steekproef van 
de Nederlandse bevolking (het PHARMO RLS systeem). Derhalve werd een 
landelijke case-cohort studie opzet gekozen, waarin de gehele bevolking als cohOlt 
beschouwd werd. De theoretische ovenvegingen met betrekking tot deze studie 
opzet zijn beschreven in hoofdstuk 7. In het kort komt dit erop neer dat de 
expositie bij personen met anafYlaxie of agranulocytose ("cases") vergeleken werd 
met de expositie in een referentie cohort uit de totale Nederlandse bevolking. 
De studie over anafYlaxie die is uitgevoerd met deze case-cohort studie opzet 
wordt beschreven in hoofdstuk 8. Een verhoogd relatief risico werd niet aileen 
gevonden voor glafenine, maar ook voor amoxicilline, penicillines in het 
algemeen, en de groep van analgetica. Het risico op anafYlaxie door glafenine was 
echter significant verhoogd ten opzichte van analgetica. Deze studie vonnde de 
belangrijkste aanleiding voor het terugtrekken van glafenine van de markt in een 
groot aantallanden in 1992. 
Vervolgens werd een case-cohort studie naar agranulocytose uitgevoerd. Deze 
studie liet geen hoog relatief risico zien voor mianserine, maar weI voor 
thyreostatica, sulfasalazine, en niet-steroide anti-inflammatoire geneesmiddelen 
(NSAID's) (hoofdstuk 9). De resultaten van deze studie waren in grote lijnen 
gelijk aan die van de Internationale Agranulocytose en Aplastische Anemie Studie, 
maar er werden hogere relatieve risico's en risico verschillen gevonden voor 
thyreostatica en dipyrone. 
In de uiteindelijke discussie (hoofdstuk 10), zijn de voor- en nadelen besproken 
van de landelijke case-cohort studie opzet in de fannaco-epidemiologie. Voordelen 
zijn dat er geen sprake is van recall bias, dat er minder kans is op selection bias 
dan bij een case-control studie, en het feit dat deze studie opzet geschikt is voor 
zeldzaam gebruikte geneesmiddelen. De belangrijkste beperking is dat, met 
uitzondering van geslacht en leeftijd, geen gegevens beschikbaar zijn met 
betrekking tot andere risicofactoren dan geneesmiddelgebruik. Een oplossing 
hiervoor zou zijn om zulke gegevens met regelmatige intervallen te verzamelen 
in steekproeven van het referentiecohort. Een andere beperking vormt het feit dat 
het aileen mogelijk is een incidentie te schatten van bijwerkingen die zo emstig 
zijn, dat ze bijna altijd tot ziekenhuisopname zullen leiden. 
De conclusie is, dat de landelijke case-cohort studie een relatief snelle en kosten-
effectieve studie opzet is om aan geneesmiddelen toegeschreven zeldzame 
bijwerkingen te kwantificeren. 
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